Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Definitions

• the present invention relates to compounds that may be used to inhibit kinases as well as compositions of matter, kits and articles of manufacture comprising these compounds.
• the present invention also relates to methods for inhibiting kinases as well as treatment methods using compounds according to the present invention.
• the present invention relates to methods of making the compounds of the present invention, as well as intermediates useful in such methods.
• the present invention relates to Aurora kinase inhibitors; compositions of matter, kits and articles of manufacture comprising these compounds; methods for inhibiting Aurora kinase; and methods of making Aurora kinase inhibitors.
• the present invention relates to inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides, compositions comprising the inhibitors, kits and articles of manufacture comprising the inhibitors and compositions, methods of making the inhibitors and compositions, and methods of using the inhibitors and inhibitor compositions.
• the inhibitors and compositions comprising them are useful for treating or modulating disease in which phosphoryl transferases, including kinases, may be involved, symptoms of such disease, or the effect of other physiological events mediated by phosphoryl transferases, including kinases.
• the invention also provides for methods of making the inhibitor compounds and methods for treating diseases in which one or more phosphoryl transferase, including kinase, activities is involved.
• Phosphoryl transferases are a large family of enzymes that transfer phosphorous-containing groups from one substrate to another.
• IUBMB Nomenclature Committee of the International Union of Biochemistry and Molecular Biology
• Kinases are a class of enzymes that function in the catalysis of phosphoryl transfer.
• the protein kinases constitute the largest subfamily of structurally related phosphoryl transferases and are responsible for the control of a wide variety of signal transduction processes within the cell.
• Protein kinases are thought to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar 250-300 amino acid catalytic domain.
• the protein kinases may be categorized into families by the substrates they phosphorylate (e.g., protein-tyrosine, protein-serine/threonine, histidine, etc.). Protein kinase sequence motifs have been identified that generally correspond to each of these kinase families (See, for example, Hanks, S. K.; Hunter, T., FASEB J.
• Lipid kinases constitute a separate group of kinases with structural similarity to protein kinases.
• Protein and lipid kinases can function in signaling pathways to activate or inactivate, or modulate the activity of (either directly or indirectly) the targets.
• targets may include, for example, metabolic enzymes, regulatory proteins, receptors, cytoskeletal proteins, ion channels or pumps, or transcription factors.
• Uncontrolled signaling due to defective control of protein phosphorylation has been implicated in a number of diseases and disease conditions, including, for example, inflammation, cancer, allergy/asthma, diseases and conditions of the immune system, disease and conditions of the central nervous system (CNS), cardiovascular disease, dermatology, and angiogenesis.
• a partial non- limiting list of such kinases includes abl, Aurora- A, Aurora-B, Aurora-C, ATK, bcr-abl, BIk, Brk, Btk, c-Kit, c-Met, c-Src, CDK1, CDK2, CDK4, CDK6, cRafl, CSFlR, CSK, EGFR, ErbB2, ErbB3, ErbB4, ERK, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, FLK-4, FIt-1, Fps, Frk, Fyn, Hck, IGF- 1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC,
• MAPK mitogen activated protein kinase
• Aurora kinases are serine/threonine protein kinases that have been implicated in human cancer, such as colon, breast and other solid tumors.
• Aurora-A also sometimes referred to as AIK
• Aurora-A is believed to be involved in protein phosphorylation events that regulate the cell cycle.
• Aurora-A may play a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities.
• Aurora-A, Aurora-B and Aurora-C have been found to be overexpressed (See, Bischoff et al., EMBO J., 17:3052-3065 (1998); Schumacher et al., J. Cell Biol. 143:1635-1646 (1998); Kimura et al., J. Biol. Chem., 272:13766-13771 (1997)).
• the protein kinases specifically but not limited to Aurora-A, Aurora-B and Aurora-C are especially attractive targets for the discovery of new therapeutics due to their important role in cancer, diabetes, Alzheimer's disease and other diseases.
• the present invention relates to compounds that have activity for inhibiting kinases.
• the present invention also provides compositions, articles of manufacture and kits comprising these compounds.
• a pharmaceutical composition that comprises a kinase inhibitor according to the present invention as an active ingredient.
• Pharmaceutical compositions according to the invention may optionally comprise 0.001%- 100% of one or more kinase inhibitors of this invention.
• compositions may be administered or coadministered by a wide variety of routes, including for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally.
• the compositions may also be administered or coadministered in slow release dosage forms.
• the invention is also directed to kits and other articles of manufacture for treating disease states associated with kinases.
• a kit comprising a composition comprising at least one kinase inhibitor of the present invention in combination with instructions.
• the instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
• the kit may also comprise packaging materials.
• the packaging material may comprise a container for housing the composition.
• the kit may also optionally comprise additional components, such as syringes for administration of the composition.
• the kit may comprise the composition in single or multiple dose forms.
• an article of manufacture is provided that comprises a composition comprising at least one kinase inhibitor of the present invention in combination with packaging materials.
• the packaging material may comprise a container for housing the composition.
• the container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
• the kit may also optionally comprise additional components, such as syringes for administration of the composition.
• the kit may comprise the composition in single or multiple dose forms.
• the compounds, compositions, kits and articles of manufacture are used to inhibit kinases.
• the compounds, compositions, kits and articles of manufacture are used to inhibit an Aurora kinase.
• the compounds, compositions, kits and articles of manufacture are used to treat a disease state for which kinases possess activity that contributes to the pathology and/or symptomology of the disease state.
• a compound is administered to a subject wherein kinases activity within the subject is altered, preferably reduced.
• a prodrug of a compound is administered to a subject that is converted to the compound in vivo where it inhibits kinases.
• a method of inhibiting kinases comprises contacting kinases with a compound according to the present invention.
• a method of inhibiting kinases comprises causing a compound according to the present invention to be present in a subject in order to inhibit kinases in vivo.
• a method of inhibiting kinases comprises administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits kinases in vivo. It is noted that the compounds of the present invention may be the first or second compounds.
• a therapeutic method is provided that comprises administering a compound according to the present invention.
• a method of inhibiting cell proliferation comprises contacting a cell with an effective amount of a compound according to the present invention.
• a method of inhibiting cell proliferation in a patient comprises administering to the patient a therapeutically effective amount of a compound according to the present invention.
• a method of treating a condition in a patient which is known to be mediated by kinases, or which is known to be treated by kinase inhibitors comprising administering to the patient a therapeutically effective amount of a compound according to the present invention.
• a method for using a compound according to the present invention in order to manufacture a medicament for use in the treatment of disease state which is known to be mediated by kinases, or which is known to be treated by kinase inhibitors.
• a method for treating a disease state for which kinases possess activity that contributes to the pathology and/or symptomology of the disease state comprising: causing a compound according to the present invention to be present in a subject in a therapeutically effective amount for the disease state.
• a method for treating a disease state for which kinases possess activity that contributes to the pathology and/or symptomology of the disease state comprising: administering a first compound to a subject that is converted in vivo to a second compound such that the second compound is present in the subject in a therapeutically effective amount for the disease state.
• the compounds of the present invention may be the first or second compounds.
• a method for treating a disease state for which kinases possesses activity that contributes to the pathology and/or symptomology of the disease state comprising: administering a compound according to the present invention to a subject such that the compound is present in the subject in a therapeutically effective amount for the disease state.
• the present invention is intended to encompass all pharmaceutically acceptable ionized forms (e.g., salts) and solvates (e.g., hydrates) of the compounds, regardless of whether such ionized forms and solvates are specified since it is well know in the art to administer pharmaceutical agents in an ionized or solvated form. It is also noted that unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all possible stereoisomers (e.g., enantiomers or diastereomers depending on the number of chiral centers), independent of whether the compound is present as an individual isomer or a mixture of isomers.
• pharmaceutically acceptable ionized forms e.g., salts
• solvates e.g., hydrates
• prodrugs may also be administered which are altered in vivo and become a compound according to the present invention.
• the various methods of using the compounds of the present invention are intended, regardless of whether prodrug delivery is specified, to encompass the administration of a prodrug that is converted in vivo to a compound according to the present invention.
• certain compounds of the present invention may be altered in vivo prior to inhibiting kinases and thus may themselves be prodrugs for another compound.
• Such prodrugs of another compound may or may not themselves independently have kinase inhibitory activity.
• Figure 1 is a characteristic XRPD spectrum of an amorphous form of Compound 88.
• Alicyclic means a moiety comprising a non-aromatic ring structure. Alicyclic moieties may be saturated or partially unsaturated with one, two or more double or triple bonds. Alicyclic moieties may also optionally comprise heteroatoms such as nitrogen, oxygen and sulfur. The nitrogen atoms can be optionally quaternerized or oxidized and the sulfur atoms can be optionally oxidized.
• alicyclic moieties include, but are not limited to moieties with (C 3-8 ) rings such as cyclopropyl, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cyclooctane, cyclooctene, and cyclooctadiene.
• moieties with (C 3-8 ) rings such as cyclopropyl, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cyclooctane, cyclo
• Aliphatic means a moiety characterized by a straight or branched chain arrangement of constituent carbon atoms and may be saturated or partially unsaturated with one, two or more double or triple bonds.
• alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
• alkenyl either alone or represented along with another radical, can be a (C 2-20 )alkenyl, a (C 2-15 )alkenyl, a (C 2-10 )alkenyl, a (C 2-5 )alkenyl or a (C 2-3 )alkenyl.
• alkenyl either alone or represented along with another radical, can be a (C 2 )alkenyl, a (C 3 )alkenyl or a (C 4 )alkenyl.
• alkenylene include ethene-1,2-diyl, propene-1,3-diyl, methylene-1,1-diyl, and the like.
• alkenylene either alone or represented along with another radical, can be a (C 2-20 ) alkenylene, a (C 2-15 ) alkenylene, a (C 2-10 ) alkenylene, a (C 2-5 ) alkenylene or a (C 2-3 ) alkenylene.
• alkenylene either alone or represented along with another radical, can be a (C 2 ) alkenylene, a (C 3 ) alkenylene or a (C 4 ) alkenylene.
• Alkoxy means an oxygen moiety having a further alkyl substituent. The alkoxy groups of the present invention can be optionally substituted.
• Alkyl represented by itself means a straight or branched, saturated or unsaturated, aliphatic radical having a chain of carbon atoms, optionally with one or more of the carbon atoms being replaced with an oxygen (See “oxaalkyl”), a carbonyl group (See “oxoalkyl”), a sulfur (See “thioalkyl”), or a nitrogen (See “azaalkyl”).
• oxaalkyl a carbonyl group
• sulfur See “thioalkyl”
• nitrogen See “azaalkyl”
• C 1-6 alkyl includes alkyls that have a chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like).
• 1 and 6 carbons e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-
• Alkyl represented along with another radical means a straight or branched, saturated or unsaturated aliphatic divalent radical having the number of atoms indicated or when no atoms are indicated means a bond (e.g., (C 6-10 )aryl(C 1-3 )alkyl includes, benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-thienylmethyl, 2-pyridinylmethyl and the like).
• alkyl either alone or represented along with another radical, can be a (C 1-20 )alkyl, a (C 1-15 )alkyl, a (C 1-10 )alkyl, a (C 1-5 )alkyl or a (C 1-3 )alkyl.
• alkyl either alone or represented along with another radical, can be a (C 1 )alkyl, a (C 2 )alkyl or a (C 3 )alkyl.
• Alkynyl means a straight or branched, carbon chain that contains at least one carbon-carbon triple bond (-C ⁇ C- or -C ⁇ CR, wherein R is hydrogen or a further substituent).
• alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl, 2- heptynyl and the like.
• alkynyl either alone or represented along with another radical, can be a (C 2-20 )alkynyl, a (C 2-15 )alkynyl, a (C 2-10 )alkynyl, a (C 2-5 )alkynyl or a (C 2-3 )alkynyl.
• alkynyl either alone or represented along with another radical, can be a (C 2 )alkynyl, a (C 3 )alkynyl or a (C 4 )alkynyl.
• Alkylene unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical.
• (C X )alkylene and (C X-Y )alkylene are typically used where X and Y indicate the number of carbon atoms in the chain.
• alkylene either alone or represented along with another radical, can be a (C 1-20 )alkylene, a (C 1-15 )alkylene, a (C 1-10 )alkylene, a (C 1-5 )alkylene or a (C 1-3 )alkylene.
• alkylene either alone or represented along with another radical, can be a (C 1 )alkylene, a (C 2 )alkylene or a (C 3 )alkylene.
• alkynylene include ethyne-1,2-diyl, propyne-1,3-diyl, and the like.
• alkynylene either alone or represented along with another radical, can be a (C 2-20 ) alkynylene, a (C 2-15 ) alkynylene, a (C 2-10 ) alkynylene, a (C 2-5 ) alkynylene or a (C 2-3 ) alkynylene.
• alkenylene either alone or represented along with another radical, can be a (C 2 ) alkynylene, a (C 3 ) alkynylene or a (C 4 ) alkynylene.
• Alkylidene means a straight or branched, saturated or unsaturated, aliphatic radical connected to the parent molecule by a double bond.
• (C X )alkylidene and (C X- Y )alkylidene are typically used where X and Y indicate the number of carbon atoms in the chain.
• alkylidene either alone or represented along with another radical, can be a (C 1-20 )alkylidene, a (C 1-15 )alkylidene, a (C 1-10 )alkylidene, a (C 1-5 )alkylidene or a (C 1-3 )alkylidene.
• alkylidene either alone or represented along with another radical, can be a (C 1 )alkylidene, a (C 2 )alkylidene or a (C 3 )alkylidene.
• amino means a nitrogen moiety having two further substituents where, for example, a hydrogen or carbon atom is attached to the nitrogen.
• representative amino groups include -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -NH((C 1-10 )alkyl), -N((C 1- 10 )alkyl) 2 , -NH(aryl), -NH(heteroaryl), -N(aryl) 2 , -N(heteroaryl) 2 , and the like.
• the two substituents together with the nitrogen may also form a ring.
• the compounds of the invention containing amino moieties may include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like.
• Azaalkyl means an alkyl, as defined above, except where one or more of the carbon atoms forming the alkyl chain are replaced with substituted or unsubstituted nitrogen atoms (-NR- or -NRR', wherein R and R are each independently hydrogen or further substituents).
• a (C 1-10 )azaalkyl refers to a chain comprising between
• Animal includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
• non-human mammals e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like
• non-mammals e.g., birds, and the like.
• Aromatic means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp 2 hybridized and the total number of pi electrons is equal to 4n+2.
• An aromatic ring may be such that the ring atoms are only carbon atoms or may include carbon and non-carbon atoms (see “heteroaryl”).
• Aryl means a monocyclic or polycyclic ring assembly wherein each ring is aromatic or when fused with one or more rings forms an aromatic ring assembly. If one or more ring atoms is not carbon (e.g., N, S), the aryl is a heteroaryl. (C X ) aryl and (C X-Y ) aryl are typically used where X and Y indicate the number of carbon atoms in the ring.
• aryl either alone or represented along with another radical, can be a (C 3-14 )aryl, a (C 3-10 )aryl, a (C 3-7 )aryl, a (C 8-10 )aryl or a (C 5-7 )aryl.
• aryl either alone or represented along with another radical, can be a (C 3-14 )aryl, a (C 3-10 )aryl, a (C 3-7 )aryl, a (C 8-10 )aryl or a (C 5-7 )aryl.
• aryl either alone or represented along with another radical, can be a (C 5 )aryl, a (C 6 )aryl, a (C 7 )aryl, a (C 8 )aryl., a (C 9 )aryl or a (C 10 )aryl.
• Bicycloalkyl means a saturated or partially unsaturated fused, spiro or bridged bicyclic ring assembly.
• "bicycloalkyl,” either alone or represented along with another radical can be a (C 4-15 )bicycloalkyl, a (C 4-10 )bicycloalkyl, a (C 6-10 )bicycloalkyl or a (C 8-10 )bicycloalkyl.
• "bicycloalkyl” either alone or represented along with another radical, can be a (C 8 )bicycloalkyl, a (C 9 )bicycloalkyl or a
• Bicycloaryl means a fused, spiro or bridged bicyclic ring assembly wherein at least one of the rings comprising the assembly is aromatic.
• (C X )bicycloaryl and (C X- Y )bicycloaryl are typically used where X and Y indicate the number of carbon atoms in the bicyclic ring assembly and directly attached to the ring.
• "bicycloaryl,” either alone or represented along with another radical can be a (a (C 4-15 )bicycloaryl, a (C 4-10 )bicycloaryl, a (C 6-10 )bicycloaryl or a (C 8-10 )bicycloaryl.
• "bicycloalkyl either alone or represented along with another radical, can be a (C 8 )bicycloaryl, a (C 9 )bicycloaryl or a (C 10 )bicycloaryl.
• “Bridging ring” and “bridged ring” as used herein refer to a ring that is bonded to another ring to form a compound having a bicyclic or polycyclic structure where two ring atoms that are common to both rings are not directly bound to each other.
• Nonexclusive examples of common compounds having a bridging ring include borneol, norbornane, 7-oxabicyclo[2.2.1]heptane, and the like.
• One or both rings of the bicyclic system may also comprise heteroatoms.
• Carbamoyl means the radical -OC(O)NRR' where R and R' are each independently hydrogen or further substituents.
• Carbocycle means a ring consisting of carbon atoms.
• Carbocyclic ketone derivative means a carbocyclic derivative wherein the ring contains a -CO- moiety.
• Cycloalkyl means a non-aromatic, saturated or partially unsaturated, monocyclic, bicyclic or polycyclic ring assembly.
• (C X ) cycloalkyl and (C X-Y ) cycloalkyl are typically used where X and Y indicate the number of carbon atoms in the ring assembly.
• (C 3-10 ) cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl,
• cycloalkyl either alone or represented along with another radical, can be a (C 3-14 )cycloalkyl, a (C 3-10 )cycloalkyl, a (C 3-7 )cycloalkyl, a (C 8-10 )cycloalkyl or a (C 5-7 )cycloalkyl.
• cycloalkyl either alone or represented along with another radical, can be a (C 5 )cycloalkyl, a (C 6 )cycloalkyl, a (C 7 )cycloalkyl, a (C 8 )cycloalkyl., a (C 9 )cycloalkyl or a (C 10 )cycloalkyl.
• Cycloalkylene means a divalent saturated or partially unsaturated, monocyclic, bicyclic or polycyclic ring assembly.
• (C X ) cycloalkylene and (C X-Y ) cycloalkylene are typically used where X and Y indicate the number of carbon atoms in the ring assembly.
• "cycloalkylene,” either alone or represented along with another radical can be a (C 3-14 )cycloalkylene, a (C 3-10 )cycloalkylene, a (C 3-7 )cycloalkylene, a (C 8-10 )cycloalkylene or a (C 5-7 )cycloalkylene.
• cycloalkylene either alone or represented along with another radical, can be a (C 5 )cycloalkylene, a (C 6 )cycloalkylene, a (C 7 )cycloalkylene, a (C 8 )cycloalkylene., a (C 9 )cycloalkylene or a (C 10 )cycloalkylene.
• Disease specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the “side effects” of such therapy.
• “Fused ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure when the ring atoms that are common to both rings are directly bound to each other.
• Non-exclusive examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like.
• Halo means fluoro, chloro, bromo or iodo.
• Halo-substituted alkyl as an isolated group or part of a larger group, means “alkyl” substituted by one or more "halo" atoms, as such terms are defined in this Application.
• Halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g., halo-substituted (C 1-3 )alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl,
• Heteroatom refers to an atom that is not a carbon atom. Particular examples of heteroatoms include, but are not limited to, nitrogen, oxygen, and sulfur.
• Heteroatom moiety includes a moiety where the atom by which the moiety is attached is not a carbon.
• Heteroalkyl means alkyl, as defined in this Application, provided that one or more of the atoms within the alkyl chain is a heteroatom.
• heteroatom means alkyl, as defined in this Application, provided that one or more of the atoms within the alkyl chain is a heteroatom.
• heteroalkyl either alone or represented along with another radical, can be a hetero(C 1-20 )alkyl, a hetero(C 1-15 )alkyl, a hetero(C 1-10 )alkyl, a hetero(C 1-5 )alkyl, a hetero(C 1-3 )alkyl or a hetero(C 1-2 )alkyl.
• heteroalkyl either alone or represented along with another radical, can be a hetero(C 1 )alkyl, a hetero(C 2 )alkyl or a hetero(C 3 )alkyl.
• Heterobicycloalkyl means bicycloalkyl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom.
• hetero(C 9-12 )bicycloalkyl as used in this application includes, but is not limited to, 3-aza- bicyclo[4.1.0]hept-3-yl, 2-aza-bicyclo[3.1.0]hex-2-yl, 3-aza-bicyclo[3.1.0]hex-3-yl, and the like.
• heterocycloalkyl either alone or represented along with another radical, can be a hetero(C 1-14 )bicycloalkyl, a hetero(C 4-14 )bicycloalkyl, a hetero(C 4-9 )bicycloalkyl or a hetero(C 5-9 )bicycloalkyl.
• hetero(C 1-14 )bicycloalkyl a hetero(C 4-14 )bicycloalkyl, a hetero(C 4-9 )bicycloalkyl or a hetero(C 5-9 )bicycloalkyl.
• heterocycloalkyl either alone or represented along with another radical, can be a hetero(C 5 )bicycloalkyl, hetero(C 6 )bicycloalkyl, hetero(C 7 )bicycloalkyl, hetero(C 8 )bicycloalkyl or a hetero(Cc))bicycloalkyl.
• Heterocycloalkylene means cycloalkylene, as defined in this Application, provided that one or more of the ring member carbon atoms is replaced by a heteroatom.
• heterocycloalkylene either alone or represented along with another radical, can be a hetero(C 1-13 )cycloalkylene, a hetero(C 1-9 )cycloalkylene, a hetero(C 1-6 )cycloalkylene, a hetero(C 5-9 )cycloalkylene or a hetero(C 2-6 )cycloalkylene.
• heterocycloalkylene can be a hetero(C 2 )cycloalkylene, a hetero(C 3 )cycloalkylene, a hetero(C 4 )cycloalkylene, a hetero(C 5 )cycloalkylene, a hetero(C 6 )cycloalkylene, hetero(C 7 )cycloalkylene, hetero(C 8 )cycloalkylene or a hetero(Cc))cycloalkylene.
• Heteroaryl means a monocyclic, bicyclic or polycyclic aromatic group wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon.
• Monocyclic heteroaryl groups include, but are not limited to, cyclic aromatic groups having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon.
• the nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized.
• Heteroaryl groups of this invention include, but are not limited to, those derived from furan, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrroline, thiazole, 1,3,4-thiadiazole, triazole and tetrazole.
• Heteroaryl also includes, but is not limited to, bicyclic or tricyclic rings, wherein the heteroaryl ring is fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, a cycloalkenyl ring, and another monocyclic heteroaryl or heterocycloalkyl ring.
• bicyclic or tricyclic heteroaryls include, but are not limited to, those derived from benzo[b]furan, benzo[b]thiophene, benzimidazole, imidazo[4,5- c]pyridine, quinazoline, thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, thieno[2,3- b]pyridine, indolizine, imidazo[1,2a]pyridine, quinoline, isoquinoline, phthalazine, quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine, imidazo[ 1 ,2-a]pyrimidine, imidazo[ 1 ,2-c]pyrimidine, imidazo[1,5-
• the bicyclic or tricyclic heteroaryl rings can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, cycloalkenyl or heterocycloalkyl group to which it is fused.
• the heteroaryl groups of this invention can be substituted or unsubstituted.
• "heteroaryl,” either alone or represented along with another radical can be a hetero(C 1-13 )aryl, a hetero(C 2-13 )aryl, a hetero(C 2-6 )aryl, a hetero(C 3-9 )aryl or a hetero(C 5-9 )aryl.
• heteroaryl either alone or represented along with another radical, can be a hetero(C 3 )aryl, a hetero(C 4 )aryl, a hetero(C 5 )aryl, a hetero(C 6 )aryl., a hetero(C 7 )aryl, a hetero(C 8 )aryl or a hetero(C 9 )aryl.
• Heterobicycloaryl means bicycloaryl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom.
• hetero(C 4-12 )bicycloaryl as used in this Application includes, but is not limited to, 2-amino-4-oxo-3,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl, and the like.
• heterocycloaryl either alone or represented along with another radical, can be a hetero(C 1-14 )bicycloaryl, a hetero(C 4-14 )bicycloaryl, a hetero(C 4-9 )bicycloarylor a hetero(C 5-9 )bicycloaryl.
• heterocycloaryl either alone or represented along with another radical, can be a hetero(C 5 )bicycloaryl, hetero(C 6 )bicycloaryl, hetero(C 7 )bicycloaryl, hetero(C 8 )bicycloaryl or a hetero(C 9 )bicycloaryl.
• Heterocycloalkyl means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, or S.
• Non-exclusive examples of heterocycloalkyl include piperidyl, A- morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1 ,4-diazaperhydroepinyl, 1,3-dioxanyl, 1 ,4-dioxanyl, tetrazolyl and the like.
• heterocycloalkyl either alone or represented along with another radical, can be a hetero(C 1-13 )cycloalkyl, a hetero(C 1-9 )cycloalkyl, a hetero(C 1-6 )cycloalkyl, a hetero(C 5-9 )cycloalkyl or a hetero(C 2-6 )cycloalkyl.
• heterocycloalkyl can be a hetero(C 2 )cycloalkyl, a hetero(C 3 )cycloalkyl, a hetero(C 4 )cycloalkyl, a hetero(C 5 )cycloalkyl, a hetero(C 6 )cycloalkyl, hetero(C 7 )cycloalkyl, hetero(C 8 )cycloalkyl or a hetero(C 9 )cycloalkyl.
• Haldroxy means the radical -OH.
• IC 50 means the molar concentration of an inhibitor that produces 50% inhibition of the target enzyme.
• Iminoketone derivative means a derivative comprising the moiety -C(NR)-, wherein R is a hydrogen or a further substituent.
• “Isomers” mean compounds having identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and stereoisomers that are nonsuperimposable mirror images are termed “enantiomers” or sometimes "optical isomers.” A carbon atom bonded to four nonidentical substituents is termed a "chiral center.” A compound with one chiral center has two enantiomeric forms of opposite chirality.
• a mixture of the two enantiomeric forms is termed a "racemic mixture.”
• a compound that has more than one chiral center has 2 n-1 enantiomeric pairs, where n is the number of chiral centers.
• Compounds with more than one chiral center may exist as ether an individual diastereomer or as a mixture of diastereomers, termed a "diastereomeric mixture.”
• a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center.
• Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see “Advanced Organic Chemistry", 4th edition, March, Jerry, John Wiley & Sons, New York, 1992).
• Linker providing X atom separation and "moiety providing X atom separation” between two other moieties mean that the chain of atoms directly linking the two other moieties is X atoms in length.
• X is given as a range (e.g., X 1 -X 2 )
• the chain of atoms is at least X 1 and not more than X 2 atoms in length.
• the chain of atoms can be formed from a combination of atoms including, for example, carbon, nitrogen, sulfur and oxygen atoms.
• each atom can optionally be bound to one or more substituents, as valencies allow.
• the chain of atoms can form part of a ring.
• a moiety providing X atom separation between two other moieties can be represented by R-(L) X -R where each L is independently selected from the group consisting of CR"R'", NR"", O, S, CO,
• "Nitro" means the radical -NO 2 .
• Oxaalkyl means an alkyl, as defined above, except where one or more of the carbon atoms forming the alkyl chain are replaced with oxygen atoms (-O- or -OR, wherein R is hydrogen or a further substituent).
• an oxa(C 1-10 ) alkyl refers to a chain comprising between 1 and 10 carbons and one or more oxygen atoms.
• the carbonyl group may be an aldehyde, ketone, ester, amide, acid or acid halide.
• an oxo(C 1-10 )alkyl refers to a chain comprising between 1 and 10 carbon atoms and one or more carbonyl groups.
• "Oxy" means the radical -O- or -OR, wherein R is hydrogen or a further substituent. Accordingly, it is noted that the oxy radical may be further substituted with a variety of substituents to form different oxy groups including hydroxy, alkoxy, aryloxy, heteroaryloxy or carbonyloxy.
• “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.
• “Pharmaceutically acceptable salts” means salts of compounds of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic
• Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases.
• Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide.
• Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.
• Polycyclic ring includes bicyclic and multi-cyclic rings.
• the individual rings comprising the polycyclic ring can be fused, spiro or bridging rings.
• Prodrug means a compound that is convertible in vivo metabolically into an inhibitor according to the present invention.
• the prodrug itself may or may not also have kinase inhibitory activity.
• an inhibitor comprising a hydroxy group may be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound.
• esters that may be converted in vivo into hydroxy compounds include acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like.
• an inhibitor comprising an amine group may be administered as an amide that is converted by hydrolysis in vivo to the amine compound.
• Protected derivatives means derivatives of inhibitors in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of inhibitors or in themselves may be active as inhibitors. A comprehensive list of suitable protecting groups can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.
• Ring and ring assembly mean a carbocyclic or a heterocyclic system and includes aromatic and non-aromatic systems.
• the system can be monocyclic, bicyclic or poly eye lie.
• the individual rings comprising the polycyclic ring can be fused, spiro or bridging rings.
• Subject includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).
• Substituent convertible to hydrogen in vivo means any group that is convertible to a hydrogen atom by enzymological or chemical means including, but not limited to, hydrolysis and hydrogeno lysis.
• hydrolyzable groups such as acyl groups, groups having an oxycarbonyl group, amino acid residues, peptide residues, o-nitrophenylsulfenyl, trimethylsilyl, tetrahydro-pyranyl, diphenylphosphinyl, and the like.
• acyl groups include formyl, acetyl, trifluoroacetyl, and the like.
• Examples of groups having an oxycarbonyl group include ethoxycarbonyl, t-butoxycarbonyl [(CH 3 ) 3 C- OCO-], benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, vinyloxycarbonyl, ⁇ -(p- toluenesulfonyl)ethoxycarbonyl, and the like.
• Examples of suitable amino acid residues include amino acid residues per se and amino acid residues that are protected with a protecting group.
• Suitable amino acid residues include, but are mnot limited to, residues of GIy (glycine), Ala (alanine; CH 3 CH(NH 2 )CO-), Arg (arginine), Asn (asparagine), Asp (aspartic acid), Cys (cysteine), GIu (glutamic acid), His (histidine), He (isoleucine), Leu (leucine; (CH 3 ) 2 CHCH 2 CH(NH 2 )CO-), Lys (lysine), Met (methionine), Phe (phenylalanine), Pro (proline), Ser (serine), Thr (threonine), Trp (tryptophan), Tyr (tyrosine), VaI (valine), Nva (norvaline), Hse (homoserine), 4-Hyp (4-hydroxyproline), 5- HyI (5-hydroxylysine), Orn (ornithine) and ⁇ -Ala.
• Suitable protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl), arylmethyloxycarbonyl groups (such as benzyloxycarbonyl and p- nitrobenzyloxycarbonyl), t-butoxycarbonyl groups [(CH 3 ) 3 C-OCO-], and the like.
• Suitable peptide residues include petide residues comprising two to five, and optionally two to three, of the aforesaid amino acid residues.
• Such peptide residues include, but are not limited to, residues of such peptides as Ala-Ala [CH 3 CH(NH 2 )CO- NHCH(CH 3 )CO-], Gly-Phe, Nva-Nva, Ala-Phe, Gly-Gly, Gly-Gly-Gly, Ala-Met, Met- Met, Leu-Met and Ala-Leu.
• the residues of these amino acids or peptides can be present in stereochemical configurations of the D-form, the L-form or mixtures thereof.
• the amino acid or peptide residue may have an asymmetric carbon atom.
• suitable amino acid residues having an asymmetric carbon atom include residues of Ala, Leu, Phe, Trp, Nva, VaI, Met, Ser, Lys, Thr and Tyr.
• Peptide residues having an asymmetric carbon atom include peptide residues having one or more constituent amino acid residues having an asymmetric carbon atom.
• suitable amino acid protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl), arylmethyloxycarbonyl groups (such as benzyloxycarbonyl and p-nitrobenzyloxycarbonyl), t-butoxycarbonyl groups [(CH 3 ) 3 C- OCO-], and the like.
• substituents "convertible to hydrogen in vivo" include reductively eliminable hydrogenolyzable groups.
• suitable reductively eliminable hydrogenolyzable groups include, but are not limited to, arylsulfonyl groups (such as o-toluenesulfonyl); methyl groups substituted with phenyl or benzyloxy (such as benzyl, trityl and benzyloxymethyl); arylmethoxycarbonyl groups (such as benzyloxycarbonyl and o-methoxy-benzyloxycarbonyl); and halogenoethoxycarbonyl groups (such as ⁇ , ⁇ , ⁇ -trichloroethoxycarbonyl and ⁇ - iodoethoxycarbonyl) .
• Substituted or unsubstituted means that a given moiety may consist of only hydrogen substituents through available valencies (unsubstituted) or may further comprise one or more non-hydrogen substituents through available valencies (substituted) that are not otherwise specified by the name of the given moiety.
• isopropyl is an example of an ethylene moiety that is substituted by -CH 3 .
• a non-hydrogen substituent may be any substituent that may be bound to an atom of the given moiety that is specified to be substituted.
• substituents include, but are not limited to, aldehyde, alicyclic, aliphatic, (C 1-10 )alkyl, alkylene, alkylidene, amide, amino, aminoalkyl, aromatic, aryl, bicycloalkyl, bicycloaryl, carbamoyl, carbocyclyl, carboxyl, carbonyl group, cycloalkyl, cycloalkylene, ester, halo, heterobicycloalkyl, heterocycloalkylene, heteroaryl, heterobicycloaryl, heterocycloalkyl, oxo, hydroxy, iminoketone, ketone, nitro, oxaalkyl, and oxoalkyl moieties, each of which may optionally also be substituted or unsubstituted.
• substituents include, but are not limited to, hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, imino(C 1-10 )alky
• examples of the further substituent include, but are not limited to, hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, imino(C 1-10 )al
• Sulfinyl means the radical -SO- and/or -SO-R, wherein R is hydrogen or a further substituent. It is noted that the sulfinyl radical may be further substituted with a variety of substituents to form different sulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters, and sulfoxides.
• Sulfonyl means the radical -SO 2 - and/or -SO 2 -R, wherein R is hydrogen or a further substituent. It is noted that the sulfonyl radical may be further substituted with a variety of substituents to form different sulfonyl groups including sulfonic acids, sulfonamides, sulfonate esters, and sulfones.
• “Therapeutically effective amount” means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.
• Thioalkyl means an alkyl, as defined above, except where one or more of the carbon atoms forming the alkyl chain are replaced with sulfur atoms (-S- or -S-R, wherein
• R is hydrogen or a further substituent).
• a thio(C 1-10 ) alkyl refers to a chain comprising between 1 and 10 carbons and one or more sulfur atoms.
• Treatment or “treating” means any administration of a compound of the present invention and includes:
• a C 1 alkyl indicates that there is one carbon atom but does not indicate what are the substituents on the carbon atom.
• a (C 1 ) alkyl comprises methyl (i.e., -CH 3 ) as well as -CRR'R where R, Rand R" may each independently be hydrogen or a further substituent where the atom attached to the carbon is a heteroatom or cyano.
• CF 3 , CH 2 OH and CH 2 CN for example, are all (C 1 ) alkyls.
• terms such as alkylamino and the like comprise dialkylamino and the like.
• Crystal refers to a material that contains a specific compound, which may be hydrated and/or solvated, and has sufficient crystalline content to exhibit a discernable diffraction pattern by XRPD or other diffraction techniques. Often, a crystalline material that is obtained by direct crystallization of a compound dissolved in a solution or interconversion of crystals obtained under different crystallization conditions, will have crystals that contain the solvent used in the crystallization, termed a crystalline solvate.
• crystallization conditions may result in the crystalline material having physical and chemical properties that are unique to the crystallization conditions, generally due to the orientation of the chemical moieties of the compound with respect to each other within the crystal and/or the predominance of a specific polymorphic form of the compound in the crystalline material.
• various amounts of the compound in an amorphous solid state may also be present, either as a side product of the initial crystallization, and/or a product of degradation of the crystals comprising the crystalline material.
• the composition may include amorphous content; the presence of the crystalline material among the amorphous material being detectably among other methods by the composition having a discernable diffraction pattern.
• the amorphous content of a crystalline material may be increased by grinding or pulverizing the material, which is evidenced by broadening of diffraction and other spectral lines relative to the crystalline material prior to grinding. Sufficient grinding and/or pulverizing may broaden the lines relative to the crystalline material prior to grinding to the extent that the XRPD or other crystal specific spectrum may become undiscernable, making the material substantially amorphous or quasi-amorphous.
• Amorphous refers to a composition comprising a compound that contains too little crystalline content of the compound to yield a discernable pattern by XRPD or other diffraction techniques.
• Glassy materials are a type of amorphous material. Amorphous materials do not have a true crystal lattice, and are consequently glassy rather than true solids, technically resembling very viscous noncrystalline liquids. Rather than being true solids, glasses may better be described as quasi- solid amorphous material. Thus, an amorphous material refers to a quasi-solid, glassy material.
• the baseline spectrum is often that of an unmanipulated crystalline form of a specific compound as obtained directly from a given set of physical and chemical conditions, including solvent composition and properties such as temperature and pressure.
• broadened can be used to describe the spectral lines of a XRPD spectrum of ground or pulverized material comprising a crystalline compound relative to the material prior to grinding.
• kinase inhibitors of the present invention comprise the formula: or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
• Z, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 1 is -Y 1 -R 12 , or R 1 is absent when Z 1 is N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N, or R 1 and R 2 are taken together to form a ring;
• Y 1 , Y 2 and Y 3 are each independently absent or a linker providing 1 or 2 atom separation between R 12 , R 13 or R 14 and the ring to which Y 1 , Y 2 or Y 3 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 4 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, carbonyl, amino, (C 1-5 )alkylamino, (C 1-5 )alkyl, halo(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, amino (C 1-5 )alkyl, aryl(C 1-5 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-6 )cycloalkyl and hetero(C 3-6 )cycloalkyl, each substituted or unsubstituted, with the proviso that R 4 is absent when the atom to which it is bound is N;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted, with the proviso that R 7 is absent when the atom to which it is bound is N;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 14 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• Y 3 -R 14 is not H when Z, Z 1 , Z 2 , Z 3 and Z 5 are all C; R 5 is a substituted amino group; and R 2 is methoxy or R 7 is methyl or amino.
• R 14 is not 3- chlorophenyl when R 1 , R 5 , R 6 and R 7 are each H; Z and Z 2 are each N; R 2 and R 4 are absent; Z 1 , Z 3 , Z 4 and Z 5 are all C; and Y 3 is NH.
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• -Y 1 -R 12 is absent when Z 1 is N and
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
• R 15 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 15 is not 3-chloro when n is 1; R 1 , R 5 , R 6 and R 7 are each H; Z and Z 2 are each N; R 2 and R 4 are absent; Z 1 , Z 3 , Z 4 and Z 5 are all C; and Y 3 is NH.
• kinase inhibitors of the present invention comprise the formula:
• n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
• R 15 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• A, A 1 , A 2 , A 3 and A 4 are each independently selected from the group consisting of CR 25 and N;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• a 1 is not CCl when A, A 2 , A 3 and A 4 are each CH; R 1 , R 5 , R 6 and R 7 are each H; Z and Z 2 are each N; R 2 and R 4 are absent; Z 1 , Z 3 , Z 4 and Z 5 are all C; and Y 3 is NH.
• kinase inhibitors of the present invention comprise the formula:
• A, A 1 , A 2 , A 3 and A 4 are each independently selected from the group consisting of CR 25 and N;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• A, A 1 , A 2 , A 3 and A 4 are each independently selected from the group consisting of CR 25 and N;
• R 23 is selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted, or R 23 and R 12 are taken together to form a ring
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
• R 15 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
• R 15 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
• R 15 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 23 is selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted, or R 23 and R 12 are taken together to form a ring
• kinase inhibitors of the present invention comprise the formula:
• R 15 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 23 is selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted, or R 23 and R 12 are taken together to form a ring
• kinase inhibitors of the present invention comprise the formula:
• n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;
• R 15 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, imino(C 1-3 )alkyl, imino(C 1-3 )alkyl, imino(
• R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalkyl, (C 1-10
• kinase inhibitors of the present invention comprise the formula:
• A, A 1 , A 2 , A 3 and A 4 are each independently selected from the group consisting of CR 25 and N;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• A, A 1 , A 2 , A 3 and A 4 are each independently selected from the group consisting of CR 25 and N;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• A, A 1 , A 2 , A 3 and A 4 are each independently selected from the group consisting of CR 25 and N;
• R 23 is selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted, or R 23 and R 12 are taken together to form a ring
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• a 2 is selected from the group consisting of CR 25 and N;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalkyl, (C 1-10
• kinase inhibitors of the present invention comprise the formula:
• a 2 is selected from the group consisting of CR 25 and N;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalkyl, (C 1-10
• kinase inhibitors of the present invention comprise the formula:
• a 2 is selected from the group consisting of CR 25 and N;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalkyl, (C 1-10
• kinase inhibitors of the present invention comprise the formula:
• a 2 is selected from the group consisting of CR 25 and N;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 27 and R 29 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalkyl,
• kinase inhibitors of the present invention comprise the formula:
• R 16 is selected from the group consisting of amino, (C 1-10 )alkylamino, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted.
• kinase inhibitors of the present invention comprise the formula:
• R 16 is selected from the group consisting of amino, (C 1-10 )alkylamino, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted.
• kinase inhibitors of the present invention comprise the formula:
• R 16 is selected from the group consisting of amino, (C 1-10 )alkylamino, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted.
• kinase inhibitors of the present invention comprise the formula:
• R 16 is selected from the group consisting of amino, (C 1-10 )alkylamino, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted.
• kinase inhibitors of the present invention comprise the formula:
• A is selected from the group consisting of CR 25 and N;
• R 16 is selected from the group consisting of amino, (C 1-10 )alkylamino, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted;
• R 23 and R 24 are each independently selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted, or R 23 and R 24 are taken together to
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• A is selected from the group consisting of CR 25 and N;
• R 16 is selected from the group consisting of amino, (C 1-10 )alkylamino, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 26 is selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted.
• kinase inhibitors of the present invention comprise the formula:
• A is selected from the group consisting of CR 25 and N;
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• R 22 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 23 is selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted, or R 23 and R 22 are taken together to form a ring
• kinase inhibitors of the present invention comprise the formula: or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, wherein
• R 2 is -Y 9 -R 13 ,
• Y 2 is absent or a linker providing 1 or 2 atom separation between R 13 and the ring to which Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 4 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, carbonyl, amino, (C 1-5 )alkylamino, (C 1-5 )alkyl, halo(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, amino (C 1-5 )alkyl, aryl(C 1-5 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-6 )cycloalkyl and hetero(C 3-6 )cycloalkyl, each substituted or unsubstituted; R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamin
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )al
• R 16 is selected from the group consisting of amino, (C 1-10 )alkylamino, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted; and
• R 23 is selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted, or R 23 and R 12 are taken together to form a substituted
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• Amorphous Form characterized by physical properties which comprise one or more of the following:
• (a) may be formed by lyophilizing a solution of Compound 88 in ACN and water;
• kinase inhibitors of the present invention comprise the formula:
• Q is selected from the group consisting of CR 1 and N;
• A, A 1 , A 2 , A 3 and A 4 are each independently selected from the group consisting of CR 25 and N;
• R 1 is -Y 1 -R 12 ;
• R 2 is -Y 2 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• kinase inhibitors of the present invention comprise the formula:
• A, A 1 , A 2 , A 3 and A 4 are each independently selected from the group consisting of CR 25 and N;
• R 1 is -Y 1 -R 12 ;
• R 2 is -Y 2 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl,
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 30 and R 31 are each independently selected from the group consisting of hydrogen, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, aza(C 1-10 )alkyl, imino(C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alky
• kinase inhibitors of the present invention comprise the formula:
• kinase inhibitors of the present invention comprise the formula:
• R 16 is selected from the group consisting of amino, (C 1-10 )alkylamino, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted.
• kinase inhibitors of the present invention comprise the formula:
• the present invention relates to processes for preparing compounds of the present invention.
• the process comprises: reacting a compound comprising the formula with a compound comprising the formula
• Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 1 is -Y 1 -R 12 , or R 1 is absent when Z 1 is N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N, or R 1 and R 2 are taken together to form a ring;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 4 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, carbonyl, amino, (C 1-5 )alkylamino, (C 1-5 )alkyl, halo(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, amino (C 1-5 )alkyl, aryl(C 1-5 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-6 )cycloalkyl and hetero(C 3-6 )cycloalkyl, each substituted or unsubstituted, with the proviso that R 4 is absent when the atom to which it is bound is N; R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted, with the proviso that R 7 is absent when the atom to which it is bound is N;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• X 1 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalkyl, (C 1-10
• the process further comprises: treating the fourth reaction product under conditions that form a compound comprising the formula
• Y 3 is absent or a linker providing 1 or 2 atom separation between R 14 and the ring to which Y 3 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur; and
• R 14 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• the process comprises: reacting a compound comprising the formula
• Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N;
• Y 2 and Y 3 are each independently absent or a linker providing 1 or 2 atom separation between R 13 or R 14 and the ring to which Y 2 or Y 3 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 4 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, carbonyl, amino, (C 1-5 )alkylamino, (C 1-5 )alkyl, halo(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, amino (C 1-5 )alkyl, aryl(C 1-5 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-6 )cycloalkyl and hetero(C 3-6 )cycloalkyl, each substituted or unsubstituted, with the proviso that R 4 is absent when the atom to which it is bound is N; R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy
• R 13 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 14 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• P is a protecting group
• X 2 and X 3 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalky
• Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N;
• Y 2 and Y 3 are each independently absent or a linker providing 1 or 2 atom separation between R 13 or R 14 and the ring to which Y 2 or Y 3 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 4 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, carbonyl, amino, (C 1-5 )alkylamino, (C 1-5 )alkyl, halo(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, amino (C 1-5 )alkyl, aryl(C 1-5 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-6 )cycloalkyl and hetero(C 3-6 )cycloalkyl, each substituted or unsubstituted, with the proviso that R 4 is absent when the atom to which it is bound is N;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted, with the proviso that R 7 is absent when the atom to which it is bound is N;
• R 13 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfmyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10
• R 14 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• the process comprises: reacting a compound comprising the formula
• Z, Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N;
• Y 2 and Y 3 are each independently absent or a linker providing 1 or 2 atom separation between R 13 or R 14 and the ring to which Y 2 or Y 3 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 4 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, carbonyl, amino, (C 1-5 )alkylamino, (C 1-5 )alkyl, halo(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, amino (C 1-5 )alkyl, aryl(C 1-5 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-6 )cycloalkyl and hetero(C 3-6 )cycloalkyl, each substituted or unsubstituted, with the proviso that R 4 is absent when the atom to which it is bound is N;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 13 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 14 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 23 and R 24 are each independently selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, aryl and heteroaryl, each substituted or unsubstituted, or R 23 and R 24 are taken together to
• Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N;
• Y 2 and Y 3 are each independently absent or a linker providing 1 or 2 atom separation between R 13 or R 14 and the ring to which Y 2 or Y 3 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted, with the proviso that R 7 is absent when the atom to which it is bound is N;
• R 13 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalkyl, (C 1-10
• the process further comprises treating the fifth reaction product under conditions that form a compound comprising the formula
• R 1 is -Y 1 -R 12 ;
• Y 1 is absent or a linker providing 1 or 2 atom separation between R 12 and the ring to which Y 1 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur; and
• R 12 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• the process comprises: reacting a compound comprising the formula with a compound comprising the formula
• G 1 , G 2 , G 3 , G 4 and G 5 are each independently a leaving group.
• the process comprises: reacting a compound comprising the formula with a compound comprising the formula under conditions that form a first reaction product comprising the formula
• the process comprises: reacting a compound comprising the formula
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 1 is -Y 1 -R 12 ;
• R 2 is -Y 2 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10
• R 30 and R 31 are each independently selected from the group consisting of hydrogen, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, aza(C 1-10 )alkyl, imino(C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alky
• X 4 , G 1 , G 2 , G 3 , G 4 , G 5 and G 6 are each independently a leaving group.
• the process comprises: reacting a compound comprising the formula
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 1 is -Y 1 -R 12 ;
• R 2 is -Y 2 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 25 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10
• R 30 and R 31 are each independently selected from the group consisting of hydrogen, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, aza(C 1-10 )alkyl, imino(C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alky
• X 5 , X 6 , G 7 , G 8 , G 9 , G 10 , G 11 and G 12 are each independently a leaving group.
• the present invention relates to compounds useful in preparing compounds of the present invention.
• such compounds comprise a formula
• X 1 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalkyl, (C 1-10
• Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 1 is -Y 1 -R 12 , or R 1 is absent when Z 1 is N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N, or R 1 and R 2 are taken together to form a ring;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 4 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, carbonyl, amino, (C 1-5 )alkylamino, (C 1-5 )alkyl, halo(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, amino (C 1-5 )alkyl, aryl(C 1-5 )alky
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted, with the proviso that R 7 is absent when the atom to which it is bound is N; and
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfmyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl
• Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N;
• Y 2 and Y 3 are each independently absent or a linker providing 1 or 2 atom separation betweenR 13 or R 14 and the ring to which Y 2 or Y 3 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfmyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted, with the proviso that R 7 is absent when the atom to which it is bound is N;
• R 13 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1
• R 14 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• such compounds comprise a formula
• Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N; R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N;
• Y 2 is absent or a linker providing 1 or 2 atom separation between R 13 and the ring to which Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 4 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, carbonyl, amino, (C 1-5 )alkylamino, (C 1-5 )alkyl, halo(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, amino (C 1-5 )alkyl, aryl(C 1-5 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-6 )cycloalkyl and hetero(C 3-6 )cycloalkyl, each substituted or unsubstituted, with the proviso that R 4 is absent when the atom to which it is bound is N;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfmyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted, with the proviso that R 7 is absent when the atom to which it is bound is N; and
• R 13 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10
• Z, Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N;
• Y 2 and Y 3 are each independently absent or a linker providing 1 or 2 atom separation between R 13 or R 14 and the ring to which Y 2 or Y 3 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 4 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, carbonyl, amino, (C 1-5 )alkylamino, (C 1-5 )alkyl, halo(C 1-5 )alkyl, carbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, amino (C 1-5 )alkyl, aryl(C 1-5 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-6 )cycloalkyl and hetero(C 3-6 )cycloalkyl, each substituted or unsubstituted, with the proviso that R 4 is absent when the atom to which it is bound is N; R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted, with the proviso that R 7 is absent when the atom to which it is bound is N;
• R 13 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 14 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• Z 2 , Z 3 , Z 4 and Z 5 are each independently selected from the group consisting of C and N;
• R 2 is -Y 2 -R 13 , or R 2 is absent when Z 2 is N;
• Y 2 is absent or a linker providing 1 or 2 atom separation betweenR 13 and the ring to which Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted, with the proviso that R 7 is absent when the atom to which it is bound is N;
• R 13 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl,
• R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, (C 1-10 )azaalkyl, (C 1-10 )oxaalkyl, (C 1-10
• such compounds comprise a formula
• G 2 is a leaving group.
• such compounds comprise a formula wherein
• G 2 is a leaving group.
• such compounds comprise a formula
• such compounds comprise a formula
• such compounds comprise a formula
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 1 is -Y 1 -R 12 ;
• R 2 is -Y 2 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• G 1 and G 4 are each independently a leaving group.
• such compounds comprise a formula
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 1 is -Y 1 -R 12 ;
• R 2 is -Y 2 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )al
• R 30 and R 31 are each independently selected from the group consisting of hydrogen, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, aza(C 1-10 )alkyl, imino(C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alky
• G 1 is a leaving group.
• such compounds comprise a formula wherein
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 1 is -Y 1 -R 12 ;
• R is -Y 9 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 30 and R 31 are each independently selected from the group consisting of hydrogen, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, aza(C 1-10 )alkyl, imino(C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alky
• G 10 is a leaving group.
• such compounds comprise a formula
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 1 is -Y 1 -R 12 ;
• R 2 is -Y 2 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 30 and R 31 are each independently selected from the group consisting of hydrogen, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, aza(C 1-10 )alkyl, imino(C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alky
• G 10 is a leaving group.
• such compounds comprise a formula
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 1 is -Y 1 -R 12 ;
• R 2 is -Y 2 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 30 and R 31 are each independently selected from the group consisting of hydrogen, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, aza(C 1-10 )alkyl, imino(C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alky
• Y 5 is absent or a linker providing 1, 2, 3, 4, 5, 6, 7 or 8 atom separation between the O and the N to which Y 5 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 1 is -Y 1 -R 12 ;
• R 2 is -Y 2 -R 13 ;
• Y 1 and Y 2 are each independently absent or a linker providing 1 or 2 atom separation between R 12 or R 13 and the ring to which Y 1 or Y 2 is attached, wherein the atoms of the linker providing the separation are selected from the group consisting of carbon, oxygen, nitrogen, and sulfur;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )
• R 7 is selected from the group consisting of hydrogen, halo, hydroxy, alkoxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted;
• R 12 and R 13 are each independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, ary
• R 30 and R 31 are each independently selected from the group consisting of hydrogen, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl, aza(C 1-10 )alkyl, imino(C 1-10 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alky
• Gn is a leaving group
• A is CR 25 .
• a 1 is CR 25 .
• a 2 is CR 25 .
• a 3 is CR 25 .
• a 4 is CR 25 .
• Y 1 is selected from the group consisting of -CH 2 -, -NH-, -O- and -S-.
• Y 1 is selected from the group consisting of -O-, -(CR 19 R 20 )m-, -NR 21 -, -S- and -S-CH 2 -; m is selected from the group consisting of 0, 1, 2, 3, 4 and 5; R 19 and R 20 are selected from the group consisting of hydrogen, halo, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sul
• Y 1 is -C(O)-NR 23 -; and R 23 is selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, hetero(C 3
• Y 1 is -C(O)-O-.
• Y 1 is -NR 23 -C(O)-; and R 23 is selected from the group consisting of hydrogen, carbonyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(C 1-5 )alkyl, aryl(C 1-10 )alkyl, heteroaryl(C 1-5 )alkyl, (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, hetero(C 3
• Y 2 is selected from the group consisting of-CH 2 -, -NH-, -O- and -S-.
• Y 2 is selected from the group consisting of -O-, -(CR 19 R 2 O) m m, -NR 21 -, -S- and -S-CH 2 -; m is selected from the group consisting of 0, 1, 2, 3, 4 and 5; R 19 and R 20 are selected from the group consisting of hydrogen, halo, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, s
• Y 3 is selected from the group consisting of -O-, -(CR 19 R 20 ) m -, -NR 21 -, -S- and -S-CH 2 -; m is selected from the group consisting of 0, 1, 2, 3, 4 and 5; R 19 and R 20 are selected from the group consisting of hydrogen, halo, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl,
• -Y 3 -R 14 is selected from the group consisting of aryl, heteroaryl, (C 9-12 )bicycloaryl and hetero(C 4-12 )bicycloaryl, each substituted or unsubstituted.
• Z is N.
• Z 1 is N.
• Z 2 is N.
• Z 3 is N.
• Z 4 is N.
• Z 5 is N.
• Z, Z 2 , Z 3 , Z 4 and Z 5 are each C.
• Z, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each C.
• R 1 is selected from the group consisting of hydrogen, halo, amino, alkoxy, carbonyloxy, aminocarbonyl, sulfonyl, carbonylamino, sulfonylamino, (C 1-10 )alkyl, hetero(C 3-12 )cycloalkyl and aryl, each substituted or unsubstituted.
• R 1 is a substituted or unsubstituted piperadinyl. In a further variation of the compounds and processes of each of the above embodiments and variations, R 1 is a substituted or unsubstituted 1-methyl(piperadin-4-yl).
• R 2 is selected from the group consisting of hydrogen, halo, amino, alkoxy, (C 1-10 )alkyl, hetero(C 3-12 )cycloalkyl and aryl, each substituted or unsubstituted.
• R 2 is hydrogen.
• R 4 is selected from the group consisting of hydrogen, halo and substituted or unsubstituted (C 1-5 )alkyl. In still another variation of the compounds and processes of each of the above embodiments and variations, R 4 is methyl. In yet another variation of the compounds and processes of each of the above embodiments and variations, R 4 is trifluoromethyl. In a further variation of the compounds and processes of each of the above embodiments and variations, R 4 is a substituted or unsubstituted oxaalkyl. In still a further variation of the compounds and processes of each of the above embodiments and variations, R 4 is a substituted or unsubstituted alkoxy. In yet a further variation of the compounds and processes of each of the above embodiments and variations, R 4 is a substituted or unsubstituted aryloxy.
• R 4 is-Y 4 -R 27 ; Y 4 is absent or a linker providing 1 or 2 atom separation between R 27 and the ring to which Y 4 is attached; and R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )al
• R 4 is-OR 27 and R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl,
• R 4 is-SR 27 and R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 )alkyl,
• R 4 is-NR 28 -R 27 ;
• R 27 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C 1-10 )alkoxy, (C 4-12 )aryloxy, hetero(C 1-10 )aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, hydroxy(C 1-10 )alkyl, carbonyl(C 1-10 )alkyl, thiocarbonyl(C 1-10 )alkyl, sulfonyl(C 1-10 )alkyl, sulfinyl(C 1-10 ;
• R 5 is selected from the group consisting of hydrogen, halo and substituted or unsubstituted (C 1-5 )alkyl.
• R 5 is hydrogen.
• R 5 is halo.
• R 5 is a substituted or unsubstituted (C 1-5 )alkyl.
• R 6 is selected from the group consisting of hydrogen, halo, amino, carbonyl, alkoxy and (C 1-5 )alkyl, each substituted or unsubstituted.
• R 6 is a substituted or unsubstituted (C 1-5 )alkyl.
• R 6 is halo.
• R 6 is selected from the group consisting of methyl, ethyl, isopropyl and cyclopropyl, each substituted or unsubstituted.
• R 7 is selected from the group consisting of hydrogen, hydroxy, amino and (C 1-5 )alkyl, each substituted or unsubstituted. In still a further variation of the compounds and processes of each of the above embodiments and variations, R 7 is hydrogen.
• R 12 is selected from the group consisting of hydrogen, halo, amino, alkoxy, carbonyloxy, aminocarbonyl, sulfonyl, carbonylamino, sulfonylamino, (C 1-10 )alkyl, hetero(C 3-12 )cycloalkyl and aryl, each substituted or unsubstituted.
• R 13 is selected from the group consisting of hydrogen, halo, amino, alkoxy, carbonyloxy, aminocarbonyl, sulfonyl, carbonylamino, sulfonylamino, (C 1-10 )alkyl, hetero(C 3-12 )cycloalkyl and aryl, each substituted or unsubstituted.
• R 14 is selected from the group consisting of halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfmyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl(C 1-5 )alkyl, hetero(C 3-12 )cycloalkyl(
• R 14 is selected from the group consisting of (C 3-12 )cycloalkyl, hetero(C 3-12 )cycloalkyl, (C 9-12 )bicycloalkyl, hetero(C 3-12 )bicycloalkyl, aryl, heteroaryl, (C 9-12 )bicycloaryl and hetero(C 4-12 )bicycloaryl, each substituted or unsubstituted.
• R 14 is selected from the group consisting of aryl and heteroaryl, each substituted with a substituent selected from the group consisting of halo, carbonyl, (C 1-5 )alkyl, alkoxy, aminocarbonyl, amino and sulfonyl, each substituted or unsubstituted.
• R 15 is selected from the group consisting of (C 1-10 )alkyl, -OR 22 , -C(O)-R 22 , -NR 23 -C(O)-R 22 , -C(O)-NR 23 -R 22 , -SO 2 -R 22 , -NR 23 -SO 2 -R 22 and -SO 2 -NR 23 R 24 ;
• R 22 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl,
• R 16 is -NR 23 -C(O)-R 22 ;
• R 22 is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C 1-10 )alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C 1-10 )alkyl, halo(C 1-10 )alkyl, carbonyl(C 1-3 )alkyl, thiocarbonyl(C 1-3 )alkyl, sulfonyl(C 1-3 )alkyl, sulfinyl(C 1-3 )alkyl, amino (C 1-10 )alkyl, imino(C 1-3 )alkyl, (C 3-12 )cycloalkyl
• R 22 is a substituted or unsubstituted (C 3-6 )cycloalkyl. In still another variation of the compounds and processes of each of the above embodiments and variations, R 22 is a substituted or unsubstituted cyclopropyl.
• R 23 and R 24 are taken together to form a carbocyclic or heterocyclic (C 5-10 ) ring.
• R 23 and R 24 are taken together to form a substituted or unsubstituted piperazine.
• R 23 is hydrogen
• R 25 is hydrogen
• R 27 is a substituted or unsubstituted heterocycloalkyl(C 1-3 )alkyl.
• R 27 is a substituted or unsubstituted piperadinyl(C 1-3 )alkyl.
• R 27 is a substituted or unsubstituted 1- methyl(piperadin-4-yl)(C 1-3 )alkyl.
• R 27 is a substituted or unsubstituted 1- methyl(piperadin-4-yl)methyl.
• R 27 is a substituted or unsubstituted amino(C 1-5 )alkyl.
• R 27 is a substituted or unsubstituted dimethy laminopropy 1.
• R 30 is a substituted or unsubstituted (C 1-5 )alkyl.
• R 30 is methyl.
• R 31 is a substituted or unsubstituted (C 1-5 )alkyl. In another variation of the compounds and processes of each of the above embodiments and variations, R 31 is methyl.
• P is selected from the group consisting of benzyl and p- methoxybenzyl.
• G 1 is halo.
• G 2 is halo.
• G 3 is halo.
• G 4 is halo.
• G 5 is -B(OH) 2 .
• Y 5 is a substituted or unsubstituted (C 1-5 )alkylene. In a further variation of the compounds and processes of each of the above embodiments and variations, Y 5 is ethyl. In still a further variation of the compounds and processes of each of the above embodiments and variations, Y 5 is propyl.
• N-methylcyclopropanecarboxamide 3-(dimethylamino)-N-(5-(3-(ethylsulfonyl)phenyl)-8-methoxy-3-methyl-9H- pyrido[2,3-b]indol-7-yl)-N-methylpropanamide; 5-(3-(cyclopropylcarbamoyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H- pyrido[2,3-b]indole-7-carboxamide; 4-(2-(3-chloro-5-(3-(ethylsulfonyl)phenyl)-9H-pyrido[2,3-b]indol-8- yloxy)ethyl)morpholine; 3-(3-chloro-5-(3-(ethylsulfonyl)phenyl)-9H-pyrido[2,3-b
• Particular examples of compounds according to the present invention also include, but are not limited to: 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H- pyrido[2,3-b]indole-7-carboxamide HCl salt; 5-(3-(ethylsulfonyl)phenyl)-3-methyl-8-((1-methylpiperidin-4-yl)methoxy)-9H- pyrido[2,3-b]indole HCl salt; 3-chloro-5-(3-(ethylsulfonyl)phenyl)-8-((1-methylpiperidin-4-yl)methoxy)-9H- pyrido[2,3-b]indole HCl salt; 3-(5-(3-(ethylsulfonyl)phenyl)-3-methyl-9H-pyri
• compounds according to the present invention include, but are not limited to: 5-phenyl-9H-pyrido[2,3-b]indole;
• N,N-dimethylpropan-1-amine 3-(5-(3-(ethylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)-N,N- dimethylpropan-1-amine; 2-(5-(3-(ethylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)-N,N- dimethylethanamine; 3-(3-chloro-5-(3-(ethylsulfonyl)phenyl)-9H-pyrido[2,3-b]indol-8-yloxy)-N,N- dimethylpropan-1-amine; 2-(3-chloro-5-(3-(ethylsulfonyl)phenyl)-9H-pyrido[2,3-b]indol-8-yloxy)-N,N-
• N-methylcyclopropanecarboxamide 3-(dimethylamino)-N-(5-(3-(ethylsulfonyl)phenyl)-8-methoxy-3-methyl-9H- pyrido[2,3-b]indol-7-yl)-N-methylpropanamide; 3-(3-chloro-5-(3-(ethylsulfonyl)phenyl)-9H-pyrido[2,3-b]indol-8- yloxy)propanenitrile; (3-(8-methoxy-3-methyl-9H-pyrido[2,3-b]indol-5- yl)phenyl)(morpholino)methanone;
• the compounds of the present invention may be in the form of a pharmaceutically acceptable salt, biohydrolyzable ester, biohydrolyzable amide, biohydrolyzable carbamate, solvate, hydrate or prodrug thereof.
• the compound optionally comprises a substituent that is convertible in vivo to a different substituent such as a hydrogen.
• the compound is in the form of a salt selected from the group consisting of a hydrochloric acid salt, a trifluoroacetic acid salt, a toluenesulfonic acid salt, a benzenesulfonic acid salt, a methanesulfonic acid salt, a succinic acid salt, a tartaric acid salt, a citric acid salt, a fumaric acid salt, a sulfuric acid salt, a phosphoric acid salt, a benzoic acid salt, a bis-hydrogen chloride salt, a bis- trifluoroacetic acid salt, a tosylate salt, a hemi-fumarate salt, a lactic acid salt, a malic acid salt, a hippuric acid salt and a hydrobromic acid salt.
• a salt selected from the group consisting of a hydrochloric acid salt, a trifluoroacetic acid salt, a toluenesulfonic acid salt, a benzen
• the compound is in the form of a salt selected from the group consisting of a hydrochloric acid salt, a toluenesulfonic acid salt, a hemi- fumarate salt, and a hippuric acid salt.
• the compound is in the form of a hydrochloric acid salt.
• the hydrochloric acid salt is formed in acetonitrile.
• the compound is in the form of a hemi-fumarate salt.
• the hemi-fumarate salt is formed in methanol.
• the compounds of the present invention may optionally be solely or predominantly in the enol tautomer in its active state. It is further noted that the compound may be present in a mixture of stereoisomers, or the compound may comprise a single stereoisomer.
• compositions comprising, as an active ingredient, a compound according to any one of the above embodiments and variations.
• the composition may be a solid or liquid formulation adapted for oral administration.
• the pharmaceutical composition may be a tablet.
• the pharmaceutical composition may be a liquid formulation adapted for parenteral administration.
• the pharmaceutical composition comprising a compound according to any one of the above embodiments and variations wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, and intrathecally.
• the pharmaceutical composition comprising: a compound having the formula
• Amorphous Form wherein at least a portion of the compound is present as Amorphous Form, characterized by physical properties which comprise one or more of the following:
• (a) may be formed by lyophilizing a solution of Compound 88 in ACN and water;
• the pharmaceutical composition comprising: a compound having the formula wherein at least a portion of the compound is present as Amorphous Form characterized by physical properties which compriseone or more of the following:
• (a) may be formed by lyophilizing a solution of Compound 88 in ACN and water;
• between 0.1% and 100% of the compound (by weight) is present in the composition as Amorphous Form. In a further variation of the above embodiments, between 0.1% and 99% of the compound (by weight) is present in the composition as Amorphous Form. In still another variation of the above embodiments, greater than 0.1% of the compound (by weight) is present in the composition as Amorphous Form. In yet another variation of the above embodiments, greater than 1% of the compound (by weight) is present in the composition as Amorphous Form. In another variation of the above embodiments, greater than 5% of the compound (by weight) is present in the composition as Amorphous Form.
• greater than 10% of the compound (by weight) is present in the composition as Amorphous Form. In yet another variation of the above embodiments, greater than 50% of the compound (by weight) is present in the composition as Amorphous Form. In a further variation of the above embodiments, greater than 75% of the compound (by weight) is present in the composition as Amorphous Form. In still a further variation of the above embodiments, greater than 90% of C the compound (by weight) is present in the composition as Amorphous Form. In yet a further variation of the above embodiments, greater than 99% of the compound (by weight) is present in the composition as Amorphous Form.
• the composition is a pill or capsule adapted for oral administration.
• the composition is in an oral dosage form selected from the group consisting of pills, tablets, capsules, emulsions, suspensions, microsuspensions, wafers, sprinkles, chewing gum, powders, lyophilized powders, granules, and troches.
• the composition is in a parenteral dosage form selected from the group consisting of suspensions, microsuspensions, emulsions, solid forms suitable for suspension or emulsification prior to injection, and implantable devices.
• the composition is adapted for topical or transdermal administration.
• the composition is in a topical or transdermal dosage form selected from the group consisting of suspensions, microsuspensions, emulsions, creams, gels, ointments, lotions, tinctures, pastes, powders, foams, aerosols, irrigations, sprays, suppositories, bandages, and dermal patches.
• the composition is in a pulmonary dosage form selected from the group consisting of powders, aerosols, suspensions, microsuspensions, and emulsions.
• the polymorphic form of the compound is at least partially preserved for a period of time following administration.
• the invention also provides a kit comprising a compound or composition according to any one of the above embodiments and variations, and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound.
• the kit comprises the compound or composition in a multiple dose form.
• the present invention provides an article of manufacture comprising a compound or composition according to any one of the above embodiments and variations, and packaging materials.
• the packaging material comprises a container for housing the compound or composition.
• the container optionally comprises a label indicating a disease state for which the compound or composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the compound or composition.
• the article of manufacture optionally comprises the compound or composition in a multiple dose form.
• the present invention provides a therapeutic method comprising administering a compound or composition according to any one of the above embodiments and variations to a subject.
• the present invention provides a method of inhibiting a kinase comprising contacting a kinase with a compound or composition according to any one of the above embodiments and variations.
• a method of inhibiting kinase comprising causing a compound or composition according to any one of the above embodiments and variations to be present in a subject in order to inhibit kinase in vivo.
• a method of treating a disease state for which a kinase possesses activity that contributes to the pathology and/or symptomology of the disease state comprising administering a compound of any one of the above embodiments and variations to a subject, wherein the compound is present in the subject in a therapeutically effective amount for the disease state.
• the present invention also provides a method of inhibiting a kinase comprising administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits kinase in vivo, the second compound being a compound according to any one of the above embodiments and variations.
• a method of preventing or treating a disease state for which a kinase possesses activity that contributes to the pathology and/or symptomology of the disease state comprising causing a compound or composition according to any one of the above embodiments and variations to be present in a subject in a therapeutically effective amount for the disease state.
• the present invention also provides a method of preventing or treating a disease state for which a kinase possesses activity that contributes to the pathology and/or symptomology of the disease state comprising administering a first compound to a subject that is converted in vivo to a second compound according to any one of the above embodiments and variations wherein the second compound is present in a subject in a therapeutically effective amount for the disease state.
• a method of preventing or treating a disease state for which a kinase possesses activity that contributes to the pathology and/or symptomology of the disease state comprising administering a compound or composition according to any one of the above embodiments and variations, wherein the compound or composition is present in the subject in a therapeutically effective amount for the disease state.
• the kinase is optionally an
• the kinase is an Aurora-B kinase.
• a method for treating cancer comprising administering a therapeutically effective amount of a compound or composition of the present invention to a mammalian species in need thereof.
• the cancer is selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, non small-cell lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer, gastrointestinal cancer, thyroid cancer, skin cancer, kidney cancer, rectal cancer, colonic cancer, cervical cancer, mesothelioma, pancreatic cancer, liver cancer, uterus cancer, cerebral tumor cancer, urinary bladder cancer and blood cancers including multiple myeloma.
• the compound or method is useful for inhibiting growth of cancer, for suppressing metastasis of cancer, for suppressing apop
• a method for treating inflammation, inflammatory bowel disease, psoriasis, or transplant rejection comprising administration to a mammalian species in need thereof of a therapeutically effective amount of a compound or composition according to the present invention.
• a method for preventing or treating amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, Parkinson's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication comprising administration to a mammalian species in need thereof of a therapeutically effective amount of a compound or composition according to any one of the above embodiments.
• a method for preventing or treating mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late -Life Forgetfulness, memory impairment and cognitive impairment and androgenetic alopecia comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound or composition according to any one of the above embodiments.
• a method for preventing or treating dementia related diseases, Alzheimer's Disease and conditions associated with kinases comprising administration to a mammalian species in need thereof of a therapeutically effective amount of a compound or composition according to any one of the above embodiments.
• the dementia related diseases are selected from the group consisting of Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies, predemented states, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and dementia pugilistica.
• a method for treating arthritis comprising administration to a mammalian species in need thereof of a therapeutically effective amount of a compound or composition according to any one of the above embodiment.
• a compound according to any one of the above embodiments and variations for use as a medicament there is provided a compound according to any one of the above embodiments and variations for use in the manufacture of a medicament for inhibiting a kinase.
• a compound according to any one of the above embodiments and variations for use in the manufacture of a medicament for treating a disease state for which a kinase possesses activity that contributes to the pathology and/or symptomology of the disease state.
• a compound according to any one of the above embodiments and variations for use in the manufacture of a medicament for treating cancer, inflammation, inflammatory bowel disease, psoriasis, transplant rejection, amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, Parkinson's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, contraception, mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late -Life Forgetfulness, memory impairment, cognitive impairment, androgenetic alopecia, dementia related diseases, and Alzheimer's Disease.
• the compounds of the present invention may be present and optionally administered in the form of salts, hydrates and prodrugs that are converted in vivo into the compounds of the present invention.
• the compounds of the present invention possess a free base form
• the compounds can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide; other mineral acids and their corresponding salts such as sulfate, nitrate, phosphate, etc.; and alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate; and other organic acids and their corresponding salts such as acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate and ascorbate.
• a pharmaceutically acceptable inorganic or organic acid e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide
• other mineral acids and their corresponding salts such as sulfate, n
• Further acid addition salts of the present invention include, but are not limited to: adipate, alginate, arginate, aspartate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptaoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate, lactobionate, malate, malonate, man
• a pharmaceutically acceptable base addition salt can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
• bases include alkali metal hydroxides including potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, e.g. potassium ethanolate and sodium propanolate; and various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N- methylglutamine.
• aluminum salts of the compounds of the present invention are alkali metal hydroxides including potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, e.g. potassium ethanolate and sodium propanolate; and various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N- methylglutamine.
• aluminum salts of the compounds of the present invention are also included.
• Organic base salts of the present invention include, but are not limited to: copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium and zinc salts.
• Organic base salts include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, e.g., arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl
• Compounds of the present invention that comprise basic nitrogen-containing groups may be quaternized with such agents as (C 1-4 ) alkyl halides, e.g., methyl, ethyl, iso- propyl and tert-butyl chlorides, bromides and iodides; di (C 1-4 ) alkyl sulfates, e.g., dimethyl, diethyl and diamyl sulfates; (C 10-18 ) alkyl halides, e.g., decyl, dodecyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aryl (C 1-4 ) alkyl halides, e.g., benzyl chloride and phenethyl bromide.
• Such salts permit the preparation of both water- soluble and oil-soluble compounds of the present invention.
• N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art.
• N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 °C.
• an oxidizing agent e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like
• a suitable inert organic solvent e.g., a halogenated hydrocarbon such as dichloromethane
• the N-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.
• Prodrug derivatives of compounds according to the present invention can be prepared by modifying substituents of compounds of the present invention that are then converted in vivo to a different substituent. It is noted that in many instances, the prodrugs themselves also fall within the scope of the range of compounds according to the present invention.
• prodrugs can be prepared by reacting a compound with a carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate,para-nitrophenyl carbonate, or the like) or an acylating agent. Further examples of methods of making prodrugs are described in Saulnier et al.(1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985.
• Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
• a "pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound according to the present invention that is utilized in the form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound.
• the pharmaceutically acceptable salt form may also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body.
• An example of a pharmacokinetic property that may be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of the compound.
• the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which it utilized.
• an aqueous solution of the compound will provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid absorption of the compound.
• a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds.
• the diastereomers may then be separated in order to recover the optically pure enantiomers.
• Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts).
• Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities.
• diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility.
• separation/resolution techniques A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981). COMPOSITION COMPRISING KINASE INHIBITORS
• compositions and administration methods may be used in conjunction with the kinase inhibitors of the present invention.
• Such compositions may include, in addition to the kinase inhibitors of the present invention, conventional pharmaceutical excipients, and other conventional, pharmaceutically inactive agents.
• the compositions may include active agents in addition to the kinase inhibitors of the present invention.
• additional active agents may include additional compounds according to the invention, and/or one or more other pharmaceutically active agents.
• compositions may be in gaseous, liquid, semi-liquid or solid form, formulated in a manner suitable for the route of administration to be used.
• routes of administration for oral administration, capsules and tablets are typically used.
• parenteral administration reconstitution of a lyophilized powder, prepared as described herein, is typically used.
• compositions comprising kinase inhibitors of the present invention may be administered or coadministered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally.
• the compounds and/or compositions according to the invention may also be administered or coadministered in slow release dosage forms.
• the kinase inhibitors and compositions comprising them may be administered or coadministered in any conventional dosage form.
• Co-administration in the context of this invention is intended to mean the administration of more than one therapeutic agent, one of which includes a kinase inhibitor, in the course of a coordinated treatment to achieve an improved clinical outcome.
• Such co-administration may also be coextensive, that is, occurring during overlapping periods of time.
• Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may optionally include one or more of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; agents for the adjustment of tonicity such as sodium chloride or dextrose, and agents for adjusting the acidity or alkalinity of the composition, such as alkaline or acidifying agents or buffers like carbonates, bicarbonates, phosphates, hydrochloric acid, and organic acids like acetic and citric acid.
• Parenteral preparations may optionally be enclosed in ampules
• kinase inhibitors according to the present invention exhibit insufficient solubility
• methods for solubilizing the compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
• DMSO dimethylsulfoxide
• surfactants such as TWEEN
• dissolution in aqueous sodium bicarbonate aqueous sodium bicarbonate
• Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.
• a solution, suspension, emulsion or the like may be formed. The form of the resulting composition will depend upon a number of factors, including the intended mode of administration, and the solubility of the compound in the selected carrier or vehicle.
• compositions according to the present invention are optionally provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, dry powders for inhalers, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds, particularly the pharmaceutically acceptable salts, preferably the sodium salts, thereof.
• the pharmaceutically therapeutically active compounds and derivatives thereof are typically formulated and administered in unit-dosage forms or multiple-dosage forms.
• Unit-dose forms refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art.
• Each unit- dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent.
• unit-dose forms include ampoules and syringes individually packaged tablet or capsule.
• Unit-dose forms may be administered in fractions or multiples thereof.
• a multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form.
• Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pint or gallons.
• multiple dose form is a multiple of unit-doses that are not segregated in packaging.
• the composition may comprise: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art.
• a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose
• a lubricant such as magnesium stearate, calcium stearate and talc
• a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polvinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders
• Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to form a solution or suspension.
• a carrier such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like
• the pharmaceutical composition to be administered may also contain minor amounts of auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.
• composition or formulation to be administered will, in any event, contain a sufficient quantity of a kinase inhibitor of the present invention to reduce kinases activity in vivo, thereby treating the disease state of the subject.
• Dosage forms or compositions may optionally comprise one or more kinase inhibitors according to the present invention in the range of 0.005% to 100% (weight/weight) with the balance comprising additional substances such as those described herein.
• a pharmaceutically acceptable composition may optionally comprise any one or more commonly employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum.
• compositions include solutions, suspensions, tablets, capsules, powders, dry powders for inhalers and sustained release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparing these formulations are known to those skilled in the art.
• the compositions may optionally contain 0.01%- 100% (weight/weight) of one or more kinase inhibitors, optionally 0.1- 95%, and optionally 1-95%.
• the composition comprises at least 0.1%, 0.25%, 0.5%, 1%, 5%, 10%, 25%, 50%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% (by weight) of one or more kinase inhibitors according to the present invention. In particular variations, greater than 0.1%, 1%, 5%, 10%, 25%, 50%, 75%, 80%, 85%, 90%, 95%, 97% or 99% (by weight) of one or more kinase inhibitors according to the present invention is present in the composition as a single crystalline or amorphous form.
• the composition may optionally be a pharmaceutical composition.
• the pharmaceutical composition may optionally further include one or more pharmaceutical carriers.
• Salts, preferably sodium salts, of the kinase inhibitors may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings.
• the formulations may further include other active compounds to obtain desired combinations of properties.
• Oral pharmaceutical dosage forms may be as a solid, gel or liquid.
• solid dosage forms include, but are not limited to tablets, capsules, granules, and bulk powders. More specific examples of oral tablets include compressed, chewable lozenges and tablets that may be enteric-coated, sugar-coated or film-coated.
• capsules include hard or soft gelatin capsules. Granules and powders may be provided in non- effervescent or effervescent forms. Each may be combined with other ingredients known to those skilled in the art.
• kinase inhibitors according to the present invention are provided as solid dosage forms, preferably capsules or tablets.
• the tablets, pills, capsules, troches and the like may optionally contain one or more of the following ingredients, or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a glidant; a sweetening agent; and a flavoring agent.
• binders examples include, but are not limited to, microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, sucrose and starch paste.
• lubricants examples include, but are not limited to, talc, starch, magnesium or calcium stearate, lycopodium and stearic acid.
• diluents examples include, but are not limited to, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.
• glidants examples include, but are not limited to, colloidal silicon dioxide.
• disintegrating agents examples include, but are not limited to, crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose.
• coloring agents examples include, but are not limited to, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate.
• sweetening agents examples include, but are not limited to, sucrose, lactose, mannitol and artificial sweetening agents such as sodium cyclamate and saccharin, and any number of spray-dried flavors.
• flavoring agents examples include, but are not limited to, natural flavors extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate.
• wetting agents examples include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
• anti-emetic coatings examples include, but are not limited to, fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates.
• film coatings examples include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate.
• the salt of the compound may optionally be provided in a composition that protects it from the acidic environment of the stomach.
• the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine.
• the composition may also be formulated in combination with an antacid or other such ingredient.
• dosage unit form When the dosage unit form is a capsule, it may optionally additionally comprise a liquid carrier such as a fatty oil.
• dosage unit forms may optionally additionally comprise various other materials that modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.
• Compounds according to the present invention may also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like.
• a syrup may optionally comprise, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
• the kinase inhibitors of the present invention may also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics. For example, if a compound is used for treating asthma or hypertension, it may be used with other bronchodilators and antihypertensive agents, respectively.
• Examples of pharmaceutically acceptable carriers that may be included in tablets comprising kinase inhibitors of the present invention include, but are not limited to binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, and wetting agents.
• Enteric-coated tablets because of the enteric-coating, resist the action of stomach acid and dissolve or disintegrate in the neutral or alkaline intestines.
• Sugar- coated tablets may be compressed tablets to which different layers of pharmaceutically acceptable substances are applied.
• Film-coated tablets may be compressed tablets that have been coated with polymers or other suitable coating. Multiple compressed tablets may be compressed tablets made by more than one compression cycle utilizing the pharmaceutically acceptable substances previously mentioned.
• Coloring agents may also be used in tablets. Flavoring and sweetening agents may be used in tablets, and are especially useful in the formation of chewable tablets and lozenges.
• liquid oral dosage forms examples include, but are not limited to, aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.
• aqueous solutions examples include, but are not limited to, elixirs and syrups.
• elixirs refer to clear, sweetened, hydroalcoholic preparations.
• pharmaceutically acceptable carriers examples include, but are not limited to solvents.
• solvents include glycerin, sorbitol, ethyl alcohol and syrup.
• syrups refer to concentrated aqueous solutions of a sugar, for example, sucrose. Syrups may optionally further comprise a preservative.
• Emulsions refer to two-phase systems in which one liquid is dispersed in the form of small globules throughout another liquid. Emulsions may optionally be oil-in- water or water-in-oil emulsions. Examples of pharmaceutically acceptable carriers that may be used in emulsions include, but are not limited to non-aqueous liquids, emulsifying agents and preservatives.
• Examples of pharmaceutically acceptable substances that may be used in non- effervescent granules, to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wetting agents.
• Examples of pharmaceutically acceptable substances that may be used in effervescent granules, to be reconstituted into a liquid oral dosage form, include organic acids and a source of carbon dioxide.
• Coloring and flavoring agents may optionally be used in all of the above dosage forms.
• preservatives include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol.
• non-aqueous liquids that may be used in emulsions include mineral oil and cottonseed oil.
• emulsifying agents that may be used include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate.
• suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia.
• Diluents include lactose and sucrose.
• Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as sodium cyclamate and saccharin.
• wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
• organic acids that may be used include citric and tartaric acid.
• Sources of carbon dioxide that may be used in effervescent compositions include sodium bicarbonate and sodium carbonate.
• Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof.
• flavoring agents include natural flavors extracted from plants such fruits, and synthetic blends of compounds that produce a pleasant taste sensation.
• the solution or suspension in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule.
• the solution e.g., for example, in a polyethylene glycol
• a pharmaceutically acceptable liquid carrier e.g. water
• liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells.
• vegetable oils glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells.
• propylene glycol esters e.g. propylene carbonate
• compositions designed to administer the kinase inhibitors of the present invention by parenteral administration, generally characterized by injection, either subcutaneously, intramuscularly or intravenously.
• injectables may be prepared in any conventional form, for example as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
• excipients examples include, but are not limited to water, saline, dextrose, glycerol or ethanol.
• the injectable compositions may also optionally comprise minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.
• Implantation of a slow-release or sustained-release system such that a constant level of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795) is also contemplated herein.
• the percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.
• Parenteral administration of the formulations includes intravenous, subcutaneous and intramuscular administrations.
• Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as the lyophilized powders described herein, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions.
• the solutions may be either aqueous or nonaqueous.
• suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
• suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
• pharmaceutically acceptable carriers that may optionally be used in parenteral preparations include, but are not limited to aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
• aqueous vehicles examples include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.
• nonaqueous parenteral vehicles examples include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil.
• Antimicrobial agents in bacteriostatic or fungistatic concentrations may be added to parenteral preparations, particularly when the preparations are packaged in multiple-dose containers and thus designed to be stored and multiple aliquots to be removed. Examples of antimicrobial agents that may be used include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.
• Examples of isotonic agents that may be used include sodium chloride and dextrose.
• Examples of buffers that may be used include phosphate and citrate.
• antioxidants that may be used include sodium bisulfate.
• Examples of local anesthetics that may be used include procaine hydrochloride.
• Examples of suspending and dispersing agents that may be used include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone.
• Examples of emulsifying agents that may be used include Polysorbate 80 (TWEEN 80).
• a sequestering or chelating agent of metal ions include EDTA.
• Pharmaceutical carriers may also optionally include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
• concentration of a kinase inhibitor in the parenteral formulation may be adjusted so that an injection administers a pharmaceutically effective amount sufficient to produce the desired pharmacological effect.
• concentration of a kinase inhibitor and/or dosage to be used will ultimately depend on the age, weight and condition of the patient or animal as is known in the art.
• Unit-dose parenteral preparations may be packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile, as is know and practiced in the art.
• Injectables may be designed for local and systemic administration.
• a therapeutically effective dosage is formulated to contain a concentration of at least about 0.1% w/w up to about 90% w/w or more, preferably more than 1% w/w of the kinase inhibitor to the treated tissue(s).
• the kinase inhibitor may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment will be a function of the location of where the composition is parenterally administered, the carrier and other variables that may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data.
• concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens may need to be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. Hence, the concentration ranges set forth herein are intended to be exemplary and are not intended to limit the scope or practice of the claimed formulations.
• the kinase inhibitor may optionally be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug.
• the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle.
• the effective concentration is sufficient for ameliorating the symptoms of the disease state and may be empirically determined.
• the kinase inhibitors of the present invention may also be prepared as lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures.
• the lyophilized powders may also be formulated as solids or gels.
• Sterile, lyophilized powder may be prepared by dissolving the compound in a sodium phosphate buffer solution containing dextrose or other suitable excipient. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation.
• the lyophilized powder may optionally be prepared by dissolving dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent, about 1-20%, preferably about 5 to 15%, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, typically, about neutral pH.
• a suitable buffer such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, typically, about neutral pH.
• a kinase inhibitor is added to the resulting mixture, preferably above room temperature, more preferably at about 30-35 °C, and stirred until it dissolves.
• the resulting mixture is diluted by adding more buffer to a desired concentration.
• the resulting mixture is sterile filtered or treated to remove particulates and to insure sterility, and apportioned into vials for lyophilization.
• Each vial may contain
• the kinase inhibitors of the present invention may also be administered as topical mixtures.
• Topical mixtures may be used for local and systemic administration.
• the resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.
• the kinase inhibitors may be formulated as aerosols for topical application, such as by inhalation (see, U.S. Pat. Nos.
• formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfme powder for insufflation, alone or in combination with an inert carrier such as lactose.
• the particles of the formulation will typically have diameters of less than 50 microns, preferably less than 10 microns.
• the kinase inhibitors may also be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application.
• Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the kinase inhibitor alone or in combination with other pharmaceutically acceptable excipients can also be administered.
• rectal administration may also be used.
• pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect.
• Rectal suppositories are used herein mean solid bodies for insertion into the rectum that melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients.
• Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point.
• bases examples include cocoa butter (theobroma oil), glycerin-gelatin, carbowax, (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used.
• Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. Tablets and capsules for rectal administration may be manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.
• Citric Acid Monohydrate 1.05 mg
• the invention is also directed to kits and other articles of manufacture for treating diseases associated with kinases. It is noted that diseases are intended to cover all conditions for which the kinases possesses activity that contributes to the pathology and/or symptomology of the condition.
• kits that comprises a composition comprising at least one kinase inhibitor of the present invention in combination with instructions.
• the instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
• the kit may also comprise packaging materials.
• the packaging material may comprise a container for housing the composition.
• the kit may also optionally comprise additional components, such as syringes for administration of the composition.
• the kit may comprise the composition in single or multiple dose forms.
• kits and other articles of manufacture comprising a composition that comprises one or more compounds of the present invention, wherein the one or more compounds of the present invention are present as a single crystalline or amorphous form.
• the composition comprises at least 0.1%, 0.25%, 0.5%, 1%, 5%, 10%, 25%, 50%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% of the one or more compounds of the present invention where greater than 0.1%, 1%, 5%, 10%, 25%, 50%, 75%, 80%, 85%, 90%, 95%, 97% or 99% of the one or more compounds of the present invention (by weight) is present in the composition as a single crystalline or amorphous form.
• the composition in the kits and articles of manufacture may optionally be a pharmaceutical composition.
• the pharmaceutical composition may optionally further include one or more pharmaceutical carriers.
• the pharmaceutical composition may optionally be formulated such that a portion of the one or more compounds of the present invention is present as a single crystalline or amorphous form for a period of time subsequent to administration of the pharmaceutical formulation to a human.
• an article of manufacture comprises a composition comprising at least one kinase inhibitor of the present invention in combination with packaging materials.
• the packaging material may comprise a container for housing the composition.
• the container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
• the kit may also optionally comprise additional components, such as syringes for administration of the composition.
• the kit may comprise the composition in single or multiple dose forms.
• the packaging material used in kits and articles of manufacture according to the present invention may form a plurality of divided containers such as a divided bottle or a divided foil packet.
• the container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule.
• a pharmaceutically acceptable material for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule.
• the container that is employed will depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in
• kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral, topical, transdermal and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
• dosage forms e.g., oral, topical, transdermal and parenteral
• Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed.
• kits are a dispenser designed to dispense the daily doses one at a time in the order of their intended use.
• the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen.
• a memory-aid is a mechanical counter that indicates the number of daily doses that has been dispensed.
• a memory-aid is a battery- powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
• the compounds of the present invention are stable and can be used safely.
• the compounds of the present invention are useful as kinase inhibitors for a variety of subjects (e.g., humans, non-human mammals and non-mammals).
• the optimal dose may vary depending upon such conditions as, for example, the type of subject, the body weight of the subject, the route of administration, and specific properties of the particular compound being used.
• the daily dose for oral administration to an adult is about 1 to 1000 mg, about 3 to 300 mg, about 10 to 200 mg, about 100 to 500 mg, about 150 to 450 mg, abour 200 to 400 mg, or about 200 to 300 mg. It will be appreciated that the daily dose can be given in a single administration or in multiple (e.g., 2 or 3) portions a day.
• a wide variety therapeutic agents may have a therapeutic additive or synergistic effect with kinase inhibitors according to the present invention.
• Combination therapies that comprise one or more compounds of the present invention with one or more other therapeutic agents can be used, for example, to: 1) enhance the therapeutic effect(s) of the one or more compounds of the present invention and/or the one or more other therapeutic agents; 2) reduce the side effects exhibited by the one or more compounds of the present invention and/or the one or more other therapeutic agents; and/or 3) reduce the effective dose of the one or more compounds of the present invention and/or the one or more other therapeutic agents.
• a method for treating a cell proliferative disease state comprising treating cells with a compound according to the present invention in combination with an anti-proliferative agent, wherein the cells are treated with the compound according to the present invention before, at the same time, and/or after the cells are treated with the anti-proliferative agent, referred to herein as combination therapy.
• combination therapy is intended to cover when agents are administered before or after each other (sequential therapy) as well as when the agents are administered at the same time.
• Examples of therapeutic agents that may be used in combination with kinase inhibitors include, but are not limited to, anticancer agents, alkylating agents, antibiotic agents, antimetabolic agents, hormonal agents, plant-derived agents, and biologic agents.
• Alkylating agents are polyfunctional compounds that have the ability to substitute alkyl groups for hydrogen ions. Examples of alkylating agents include, but are not limited to, bischloroethylamines (nitrogen mustards, e.g. chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, uracil mustard), aziridines (e.g.
• alkyl alkone sulfonates e.g. busulfan
• nitrosoureas e.g. carmustine, lomustine, streptozocin
• nonclassic alkylating agents altretamine, dacarbazine, and procarbazine
• platinum compounds carboplastin and cisplatin.
• These compounds react with phosphate, amino, hydroxyl, sulfihydryl, carboxyl, and imidazole groups. Under physiological conditions, these drugs ionize and produce positively charged ion that attach to susceptible nucleic acids and proteins, leading to cell cycle arrest and/or cell death.
• Combination therapy including a kinase inhibitor and an alkylating agent may have therapeutic synergistic effects on cancer and reduce sides affects associated with these chemotherapeutic agents.
• Antibiotic agents are a group of drugs that produced in a manner similar to antibiotics as a modification of natural products.
• antibiotic agents include, but are not limited to, anthracyclines (e.g. doxorubicin, daunorubicin, epirubicin, idarubicin and anthracenedione), mitomycin C, bleomycin, dactinomycin, plicatomycin.
• anthracyclines e.g. doxorubicin, daunorubicin, epirubicin, idarubicin and anthracenedione
• mitomycin C e.g. doxorubicin, daunorubicin, epirubicin, idarubicin and anthracenedione
• mitomycin C e.g. doxorubicin, daunorubicin, epirubicin, idarubicin and anthracenedione
• mitomycin C e.g. doxorubicin
• Bleomycin is generally believed to chelate iron and forms an activated complex, which then binds to bases of DNA, causing strand scissions and cell death.
• Combination therapy including a kinase inhibitor and an antibiotic agent may have therapeutic synergistic effects on cancer and reduce sides affects associated with these chemotherapeutic agents.
• Antimetabolic agents are a group of drugs that interfere with metabolic processes vital to the physiology and proliferation of cancer cells. Actively proliferating cancer cells require continuous synthesis of large quantities of nucleic acids, proteins, lipids, and other vital cellular constituents. Many of the antimetabolites inhibit the synthesis of purine or pyrimidine nucleosides or inhibit the enzymes of DNA replication.
• antimetabolites also interfere with the synthesis of ribonucleosides and RNA and/or amino acid metabolism and protein synthesis as well. By interfering with the synthesis of vital cellular constituents, antimetabolites can delay or arrest the growth of cancer cells.
• antimetabolic agents include, but are not limited to, fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate, leucovorin, hydroxyurea, thioguanine (6-TG), mercaptopurine (6-MP), cytarabine, pentostatin, fludarabine phosphate, cladribine (2- CDA), asparaginase, and gemcitabine.
• Combination therapy including a kinase inhibitor and a antimetabolic agent may have therapeutic synergistic effects on cancer and reduce sides affects associated with these chemotherapeutic agents.
• Hormonal agents are a group of drug that regulate the growth and development of their target organs. Most of the hormonal agents are sex steroids and their derivatives and analogs thereof, such as estrogens, androgens, and progestins. These hormonal agents may serve as antagonists of receptors for the sex steroids to down regulate receptor expression and transcription of vital genes. Examples of such hormonal agents are synthetic estrogens (e.g. diethylstibestrol), antiestrogens (e.g.
• Plant-derived agents are a group of drugs that are derived from plants or modified based on the molecular structure of the agents.
• plant-derived agents include, but are not limited to, vinca alkaloids (e.g., vincristine, vinblastine, vindesine, vinzolidine and vinorelbine), podophyllotoxins (e.g., etoposide (VP- 16) and teniposide (VM-26)), taxanes (e.g., paclitaxel and docetaxel).
• vinca alkaloids e.g., vincristine, vinblastine, vindesine, vinzolidine and vinorelbine
• podophyllotoxins e.g., etoposide (VP- 16) and teniposide (VM-26)
• taxanes e.g., paclitaxel and docetaxel.
• Podophyllotoxins such as etoposide are believed to interfere with DNA synthesis by interacting with topoisomerase II, leading to DNA strand scission.
• Biologic agents are a group of biomolecules that elicit cancer/tumor regression when used alone or in combination with chemotherapy and/or radiotherapy.
• biologic agents include, but are not limited to, immuno-modulating proteins such as cytokines, monoclonal antibodies against tumor antigens, tumor suppressor genes, and cancer vaccines.
• Combination therapy including a kinase inhibitor and a biologic agent may have therapeutic synergistic effects on cancer, enhance the patient's immune responses to tumorigenic signals, and reduce potential sides affects associated with this chemotherapeutic agent.
• IL-2 interleukin 2
• IL-4 interleukin 4
• IL-12 interleukin 12
• Interferon include more than 23 related subtypes with overlapping activities, all of the IFN subtypes within the scope of the present invention. IFN. has demonstrated activity against many solid and hematologic malignancies, the later appearing to be particularly sensitive.
• Other immuno-modulating agents other than cytokines may also be used in conjunction with a kinase inhibitor to inhibit abnormal cell growth.
• immuno-modulating agents include, but are not limited to bacillus Calmette-Guerin, levamisole, and octreotide, a long-acting octapeptide that mimics the effects of the naturally occurring hormone somatostatin.
• Monoclonal antibodies against tumor antigens are antibodies elicited against antigens expressed by tumors, preferably tumor-specific antigens.
• monoclonal antibody HERCEPTIN® (Trastruzumab) is raised against human epidermal growth factor receptor2 (HER2) that is overexpressed in some breast tumors including metastatic breast cancer. Overexpression of HER2 protein is associated with more aggressive disease and poorer prognosis in the clinic.
• HERCEPTIN® is used as a single agent for the treatment of patients with metastatic breast cancer whose tumors over express the HER2 protein.
• Combination therapy including kinase inhibitor and HERCEPTIN® may have therapeutic synergistic effects on tumors, especially on metastatic cancers.
• RITUXAN® (Rituximab) that is raised against CD20 on lymphoma cells and selectively deplete normal and malignant CD20 + pre-B and mature B cells.
• RITUXAN® is used as single agent for the treatment of patients with relapsed or refractory low-grade or follicular, CD20+, B cell non-Hodgkin's lymphoma.
• Combination therapy including kinase inhibitor and RITUXAN® may have therapeutic synergistic effects not only on lymphoma, but also on other forms or types of malignant tumors.
• Tumor suppressor genes are genes that function to inhibit the cell growth and division cycles, thus preventing the development of neoplasia. Mutations in tumor suppressor genes cause the cell to ignore one or more of the components of the network of inhibitory signals, overcoming the cell cycle check points and resulting in a higher rate of controlled cell growth — cancer. Examples of the tumor suppressor genes include, but are not limited to, DPC-4, NF-1, NF-2, RB, p53, WT1, BRCA1 and BRCA2. [0363] DPC-4 is involved in pancreatic cancer and participates in a cytoplasmic pathway that inhibits cell division. NF-1 codes for a protein that inhibits Ras, a cytoplasmic inhibitory protein.
• NF-1 is involved in neurofibroma and pheochromocytomas of the nervous system and myeloid leukemia.
• NF-2 encodes a nuclear protein that is involved in meningioma, schwanoma, and ependymoma of the nervous system.
• RB codes for the pRB protein, a nuclear protein that is a major inhibitor of cell cycle. RB is involved in retinoblastoma as well as bone, bladder, small cell lung and breast cancer.
• P53 codes for p53 protein that regulates cell division and can induce apoptosis. Mutation and/or inaction of p53 is found in a wide ranges of cancers. WT1 is involved in Wilms tumor of the kidneys.
• BRCA1 is involved in breast and ovarian cancer
• BRCA2 is involved in breast cancer.
• the tumor suppressor gene can be transferred into the tumor cells where it exerts its tumor suppressing functions.
• Combination therapy including a kinase inhibitor and a tumor suppressor may have therapeutic synergistic effects on patients suffering from various forms of cancers.
• TAA tumor-associated antigens
• GM2 gangliosides
• PSA prostate specific antigen
• AFP alpha- fetoprotein
• CEA carcinoembryonic antigen
• An adjuvant may be used to augment the immune response to TAAs.
• adjuvants include, but are not limited to, bacillus Calmette-Guerin (BCG), endotoxin lipopolysaccharides, keyhole limpet hemocyanin (GKLH), interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF) and Cytoxan, a chemotherapeutic agent which is believe to reduce tumor-induced suppression when given in low doses.
• BCG Bacillus Calmette-Guerin
• GKLH keyhole limpet hemocyanin
• IL-2 interleukin-2
• GM-CSF granulocyte-macrophage colony-stimulating factor
• Cytoxan a chemotherapeutic agent which is believe to reduce tumor-induced suppression when given in low doses.
• a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds.
• the diastereomers may then be separated in order to recover the optically pure enantiomers.
• Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts).
• Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities.
• diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility.
• separation/resolution techniques A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
• Compounds according to the present invention can also be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid.
• a pharmaceutically acceptable base addition salt of a compound can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base.
• Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds are set forth in the definitions section of this Application.
• the salt forms of the compounds can be prepared using salts of the starting materials or intermediates.
• the free acid or free base forms of the compounds can be prepared from the corresponding base addition salt or acid addition salt form.
• a compound in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
• a compound in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc).
• N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art.
• N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 °C.
• an oxidizing agent e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like
• a suitable inert organic solvent e.g., a halogenated hydrocarbon such as dichloromethane
• the N-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.
• Compounds in an unoxidized form can be prepared from N-oxides of compounds by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80 °C.
• a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
• an inert organic solvent e.g., acetonitrile, ethanol, aqueous dioxane, or the like
• Prodrug derivatives of the compounds can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al.(1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
• appropriate prodrugs can be prepared by reacting a non-derivatized compound with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate,para-nitrophenyl carbonate, or the like).
• Protected derivatives of the compounds can be made by methods known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, Inc. 1999.
• Compounds according to the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
• Compounds according to the present invention can also be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of compounds, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities.
• the diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility.
• the optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
• a more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
• M molar
• mM millimolar
• i.v. intravenous
• Hz Hertz
• Tr retention time
• RP reverse phase
• TEA triethylamine
• TFA trifluoroacetic acid
• TFAA trifluoroacetic anhydride
• THF tetrahydrofuran
• DME (1,2-dimethoxyethane); DCM (dichloromethane);
• DCE dichloroethane
• DMF N,N-dimethylformamide
• DMPU N,N'-dimethylpropyleneurea
• CDI 1,1-carbonyldiimidazole
• IBCF isobutyl chloroformate
• HOAc acetic acid
• HOSu N-hydroxysuccinimide
• HOBT 1-hydroxybenzotriazole
• Et 2 O diethyl ether
• EDCI ethylcarbodiimide hydrochloride
• DCC (dicyclohexylcarbodiimide); CBZ (benzyloxycarbonyl);
• TIPS triisopropylsilyl
• TBS t-butyldimethylsilyl
• BOP bis(2-oxo-3-oxazolidinyl)phosphinic chloride
• TBAF tetra-n-butylammonium fluoride
• mCPBA metal-chloroperbenzoic acid
• the starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as the Aldrich Chemical Company (Milwaukee, WI), Bachem (Torrance, CA), Sigma (St. Louis, MO), or may be prepared by methods well known to a person of ordinary skill in the art, following procedures described in such standard references as Fieser and Fieser's Reagents for Organic Synthesis, vols. 1-17, John Wiley and Sons, New York, NY, 1991; Rodd's Chemistry of Carbon Compounds, vols. 1-5 and supps., Elsevier Science Publishers, 1989; Organic Reactions, vols.
• Kinase inhibitors according to the present invention may be synthesized according to the reaction scheme shown below. Other reaction schemes could be readily devised by those skilled in the art. It should also be appreciated that a variety of different solvents, temperatures and other reaction conditions can be varied to optimize the yields of the reactions.
• Compound A and Compound B are mixed and treated under a variety of conditions to form Compound C.
• the mixture of Compound A and Compound B can be subjected to microwave irradiation, either neat or in an appropriate solvent, at temperatures ranging from 80 °C to 200 °C.
• the nitro group in Compound C is reduced by, for example, catalytic hydrogenation or metal reductions (e.g., with SnCl 2 ) to form Compound D.
• Compound D is converted to Compound E using NaNO 2 under suitable conditions (e.g., in AcOH).
• Compound E is treated with an acid (e.g., o-phosphoric acid) or under flash vacuum at 150 °C to 350 °C to obtain Compound F.
• X 1 in Compound F is halo
• Compound F can be further converted to Compound G either by treating with alcohol, amine, thiol or by Suzuki type coupling.
• Compound H is reacted with Compound I using Sonogashira type coupling to give Compound J.
• Compound J is reacted with ethynyltrimethylsilane under suitable conditions (e.g. , Pd mediated in the presence or absence of a base) to provide Compound K.
• Compound K is transformed to Compound L under Diels-Alder reaction conditions (e.g., heating to a temperature between 100 °C and 200 °C).
• the TMS group in Compound L is converted to a halo group to yield Compound M.
• Compound M is further converted to Compound N either by treating with alcohol, amine or thiol, or by Suzuki type coupling.
• Deprotection of Compound N provides Compound O.
• Compound O is treated with POX 3 to obtain Compound P.
• Compound P is further converted to Compound Q either by treating with alcohol, amine or thiol, or by Suzuki type coupling.

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=40800472

Family Applications (1)

Country Status (3)

Families Citing this family (8)

Family Cites Families (6)

• 2007
  • 2007-10-08 EP EP07868389A patent/EP2081930A2/de not_active Withdrawn
  • 2007-10-08 WO PCT/US2007/080710 patent/WO2008045834A2/en active Application Filing
  • 2007-10-08 CA CA002666130A patent/CA2666130A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events